



Predicting sleep disordered breathing in outpatients with suspected OSA

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004519
Article Type:	Research
Date Submitted by the Author:	20-Nov-2013
Complete List of Authors:	Cowan, Douglas; Glasgow Royal Infirmary, North Glasgow Sleep Service, Respiratory Department Allardice, Gwen; University of Glasgow, West of Scotland Cancer Surveillance Unit MacFarlane, Duncan; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Ramsay, Darren; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Ambler, Heather; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Banham, Stephen; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Livingston, Eric; Glasgow Royal Infirmary, North Glasgow Sleep Service, Respiratory Department Carlin, Christopher; Gartnavel General Hospital, Sleep and Breathing Support
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	Sleep medicine < ANAESTHETICS, SLEEP MEDICINE, Adult thoracic medicine < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 **Predicting sleep disordered breathing in outpatients with**
4
5
6 **suspected OSA**
7
8
9

10
11 **¹Douglas C. Cowan BMedSci, MBChB, MRCP, PhD; ²Gwen Allardice BSc,**
12
13 **MSc, PhD; ¹Duncan MacFarlane BSc; ¹Darren Ramsay BSc; ¹Heather**
14 **Ambler; ¹Stephen Banham MBChB, MD, FRCP; ¹Eric Livingston BSc,**
15 **MBChB, MD, FRCP; ¹Christopher Carlin BSc, MBChB, MRCP, PhD.**
16
17
18
19
20
21
22
23

24 **¹North Glasgow Sleep Service, Gartnavel General Hospital and Glasgow Royal**
25 **Infirmery, Glasgow, UK;**
26
27
28

29 **²West of Scotland Cancer Surveillance Unit, University of Glasgow, Glasgow,**
30 **UK.**
31
32
33
34
35
36
37

38 ***Address for correspondence:***

39 Dr Douglas C Cowan,
40 Respiratory Department,
41 Glasgow Royal Infirmery,
42 16 Alexander Parade.
43
44 Glasgow,
45
46 UK,
47
48 G31 2ER
49
50
51
52
53
54
55

56 Tel: +44 141 211 3482
57
58
59
60

1
2
3 e-mail: douglas.cowan@otago.ac.nz
4

5 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive
6 licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its
7 Licensees to permit this article (if accepted) to be published in Thorax and any other BMJPGJL products to exploit all
8 subsidiary rights, as set out in our licence
9

10
11 **Running title:** Prediction of Sleep Disordered Breathing
12

13
14 **Word count:** 2997
15

16 **Key words:** Obstructive Sleep Apnoea, Sleep Disordered Breathing, Berlin Questionnaire,
17 STOP-BANG questionnaire, prediction
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background: Validated predictors of sleep disordered breathing (SDB) are required to streamline sleep services in the face of the obesity epidemic. Berlin, STOP and STOP-BANG questionnaires are useful in other settings, but their ability to predict obstructive sleep apnoea (OSA) in the sleep clinic population is unknown. We considered the utility of these questionnaires, other patient characteristics, co-morbidities, Epworth Sleepiness Scale (ESS), exhaled nitric oxide (F_ENO) and blood markers for the prediction of SDB on limited polygraphy.

Methods: Data was obtained on 129 patients referred with possible OSA. We selected cut-points of apnoea hypopnoea index (AHI) of ≥ 5 and ≥ 15 per hour from their home polygraphy and determined associations of these with individual symptoms, questionnaire scores and other results. ROC analysis, univariate and multivariate logistic regression were used to explore these.

Results: AHI was ≥ 5 in 97 and ≥ 15 in 56 patients. STOP and STOP-BANG scores were associated with both AHI cut-points but results with ESS and Berlin Questionnaire scores were negative. STOP-BANG had a negative predictive value 1.00 (0.77-1.00) for an AHI ≥ 15 with a score ≥ 3 predicting AHI ≥ 5 with sensitivity 0.93 (95%CI 0.84-0.98) and accuracy 79%, whilst a score ≥ 6 predicted AHI ≥ 15 with specificity 0.78 (0.65-0.88) and accuracy 72%. Neck circumference ≥ 17 in and presence of witnessed apnoeas were independent predictors of SDB.

Conclusions: Both STOP and STOP-BANG questionnaires have utility for the prediction of SDB in the sleep clinic population. Modification of the STOP-BANG questionnaire merits further study in this and other patient groups.

(Word count 246)

1
2
3
4
5 Strengths and limitations of this study:
6

7 Strengths:
8

- 9
10 • This is the first study to prospectively evaluate the utility of the Berlin, STOP and
11 STOP-BANG questionnaires in the prediction of sleep disordered breathing in the
12 population referred to a sleep service for assessment of possible obstructive sleep
13 apnoea.
14
15 • This results of this study show that the STOP and STOP-BANG, but not the Berlin
16 questionnaire, have utility for prediction of sleep disordered breathing in the sleep
17 clinic population.
18
19
20
21
22
23
24

25 Weaknesses:
26

- 27
28 • This study uses home unattended limited sleep studies rather than in-hospital attended
29 full polysomnography, however this is considered standard clinical practice in the UK
30 and is considered an acceptable method for diagnosis of OSA by the American
31 Academy of Sleep Medicine.
32
33 • The sample size limits the conclusions that can be drawn from the multivariate
34 analysis, however this was a secondary objective of the study.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Obstructive sleep apnoea syndrome (OSAS) is common with prevalence of approximately 4% in middle-aged men and 2% in middle-aged women.(1) Frequent partial (hypopnoea) or complete (apnoea) upper airway collapse during sleep leads to oxygen desaturation, increased respiratory effort, arousal and sleep fragmentation.(2) Patients typically present with witnessed apnoeas, loud snoring and excessive daytime somnolence.(3) The syndrome is associated with impaired quality of life,(4) cognitive functioning and work performance,(5) and with increased risk of road traffic accidents.(6) OSAS is considered an independent risk factor for hypertension,(7) and has associations with coronary disease, stroke, heart failure, arrhythmias,(8) metabolic syndrome(9) and type 2 diabetes.(10)

Despite the substantial burden of this disease, it is under-recognised. One study estimated that 93% of females and 82% of males with moderate-severe OSAS were not clinically diagnosed,(11) and more recent data support this finding.(12) Sleep studies are required for OSAS diagnosis but are expensive and not widely available.(3) Given the recent increases in childhood(13) and adulthood obesity,(14) the workload for sleep clinics and sleep laboratories will increase. Predictors of sleep disordered breathing (SDB) are required to allow recognition of OSAS, and prioritisation of investigations.

Several questionnaires have been designed to screen for SDB in different populations. The Berlin Questionnaire was first validated in primary care against portable unattended sleep studies and a “high risk” score predicted a respiratory disturbance index >5 with sensitivity 0.86, specificity 0.77, positive predictive value 0.89 and likelihood ratio 3.79.(15) It’s utilisation in other populations has been assessed with variable success.(16-22) The STOP and STOP-BANG Questionnaires were originally validated in surgical patients using in-

1
2
3 hospital attended polysomnography.(23) For prediction of apnoea hypopnoea index (AHI)
4
5 greater than 5, 15 and 30, sensitivities for the STOP and STOP-BANG questionnaires were
6
7 65.6, 74.3 and 79.5%, and 83.9, 92.9 and 100%, respectively. The Berlin and STOP
8
9 questionnaires have been compared in a cohort of surgical patients(24) and the STOP and
10
11 STOP-BANG questionnaires have been compared in a large study involving several distinct
12
13 cardiovascular and respiratory disease cohorts.(25) No study has, however, compared these
14
15 screening tools in a sleep service-referred population. Also, along with changes in the
16
17 population (i.e. rising obesity rates) there is increasing recognition in primary care, so it is
18
19 necessary to update and re-evaluate established assessment tools in the face of the evolution
20
21 in sleep clinic practice.
22
23
24
25
26

27 The objective of this study was, firstly, to compare utility of Berlin, STOP and STOP-BANG
28
29 questionnaires for prediction of SDB in a population referred to the sleep clinic for
30
31 assessment of possible OSA. Secondly, we sought to identify the most important variables
32
33 from these questionnaires and routine sleep clinic assessment that might be utilised in the
34
35 development of a composite predictive score for future use in this population.
36
37
38
39

40 **Methods**

41
42 This was a prospective observational study conducted May-December 2012. The protocol
43
44 was approved by the West of Scotland Research Ethics Committee. Study participants
45
46 received an information sheet and provided informed consent. .
47
48
49

50 *Participants*

51
52 Consecutive patients aged ≥ 16 years referred to the North Glasgow Sleep Service (a tertiary
53
54 centre) for assessment of possible OSA were invited to participate.
55
56
57
58
59
60

Measurements

Height, weight, body mass index (BMI), neck circumference, blood pressure and Epworth Sleepiness Scale (ESS)(26) were completed at the Sleep Clinic. Participants attended the Sleep Laboratory on a separate day so that a Sleep Physiologist could provide, and instruct on fitting, a sleep study device. On that occasion, relevant symptoms and co-morbidities were recorded, Mallampatti score was assessed, and the Berlin and STOP-BANG Questionnaires were completed. Blood samples including non-fasting lipid profile, glycated haemoglobin (HbA1c) and C-reactive protein (CRP) were taken. Two fractional exhaled nitric oxide (F_ENO) measurements were taken using the NIOX MINO[®] (Aerocrine, Solna, Sweden), and the mean calculated.

Sleep Studies

Unattended home limited polygraphy sleep studies were performed using the SOMNOmedics SOMNOscreen[™] kit (Randersacker, Germany) with channels that recorded body position, thoraco-abdominal movements, oronasal airflow, heart rate, pulse oximetry and snoring. Sleep studies scoring by experienced Sleep Physiologists was in accordance with accepted guidelines.(27) An apnoea was defined as cessation of nasal flow for ≥ 10 seconds, whilst a hypnoea was defined as 50% reduction in nasal flow for ≥ 10 seconds, or lesser reduction in flow associated with oxygen desaturation of $\geq 4\%$.

The Epworth Sleepiness Scale (ESS), Berlin, STOP and STOP-BANG Questionnaires

The ESS is a validated measure of daytime sleepiness including eight questions, each with four possible responses, that assesses the likelihood of dozing in different situations; a score of $\geq 11/24$ denotes excessive daytime somnolence.(26) The Berlin Questionnaire includes

1
2
3 questions in three categories that relate firstly to snoring and witnessed apnoeas, secondly, to
4
5 tiredness, fatigue and sleepiness, and thirdly, to hypertension and obesity.(15) High risk of
6
7 OSA is defined by scoring positively in ≥ 2 categories. The STOP Questionnaire includes
8
9 four yes/no questions that relate to Snoring, Tiredness, Observed apnoeas and high blood
10
11 Pressure.(23) High risk of OSA is defined as a score of ≥ 2 . The STOP-BANG Questionnaire
12
13 includes four additional questions relating to BMI, Age, Neck circumference and Gender, and
14
15 high risk of OSA is defined as a score of ≥ 3 .(23)
16
17
18
19

20 21 *Statistical analyses*

22
23 Statistical analyses were carried out using GraphPad Prism 5, IBM SPSS Statistics 19 and
24
25 STATA 12. Normality of data was checked using D'Agostino & Pearson omnibus normality
26
27 test. A priori, two cut-points were chosen for AHI: ≥ 5 events/hour (the standard cut-point
28
29 for the diagnosis of OSA),(28) and ≥ 15 events/hour, to predict significant SDB (the standard
30
31 cut-point for initiating continuous positive airway pressure [CPAP] therapy).(28) Groups
32
33 were compared using unpaired t-tests, Mann-Whitney tests and Fisher's Exact tests as
34
35 appropriate. Sensitivities, specificities, positive and negative predictive values, positive and
36
37 negative likelihood ratios, and overall accuracies were calculated for each of the
38
39 questionnaires for prediction of SDB as defined by AHI cut-points of ≥ 5 and ≥ 15 .
40
41 Associations between individual variables and each of the cut-points for AHI were explored
42
43 using univariate and multivariate logistic regression. For multivariate analysis, in a few cases
44
45 where BMI was known but neck circumference was not known, a value for the neck
46
47 circumference was imputed using linear regression with BMI as the independent value. This
48
49 allowed for a dataset of 116 cases with all of the variables known or imputed to be built to
50
51 identify independent variables for inclusion in a composite score. Receiver operating
52
53 characteristic (ROC) curve analysis was used to assess predictive value and an area under the
54
55
56
57
58
59
60

1
2
3 curve (AUC) >0.7 was considered clinically significant. Data are presented as mean
4 (standard deviation), median (interquartile range) and proportion (percentage), unless stated
5 otherwise. A p value <0.05 was considered statistically significant.
6
7
8
9

10 11 12 **Results**

13
14 150 subjects participated in this study, of which 129 had adequate sleep study data and were
15 included in the analysis. AHI was ≥ 5 in 97/129 (75%) and ≥ 15 in 56/129 (43%). Overall, 82
16 (64%) were male, mean(SD) age was 49(11) years, and median(IQR) BMI was 32(29-39)
17 kg/m².
18
19
20
21
22
23
24

25 *Predicting SDB: Patient characteristics (See Table 1)*

26
27 An AHI <5 (“rule-out measurement”) was associated with female sex, younger age, lower
28 weight and neck circumference, less frequently reported witnessed apnoeas, higher high
29 density lipoprotein (HDL) cholesterol, and lower triglycerides, cholesterol/HDL and HbA1c.
30
31 An AHI ≥ 15 (“rule-in measurement”) was associated with male sex, obesity, higher weight,
32 BMI and neck circumference, more frequently reported hypertension and witnessed apnoeas,
33 lower HDL cholesterol, and higher triglycerides, cholesterol/HDL and HbA1c.
34
35
36
37
38
39
40
41
42

43 *Predicting SDB: ESS, Berlin, STOP and STOP-BANG (See Tables 2, 3 and 4)*

44
45 The ESS and Berlin questionnaire outcomes were not associated with either AHI cut-point.
46
47 An AHI <5 was associated with lower STOP and STOP-BANG scores, and fewer subjects
48 being classified as “high risk” for OSA by both STOP and STOP-BANG questionnaires. An
49 AHI ≥ 15 was associated with higher STOP and STOP-BANG scores and more subjects being
50 classified as “high risk” for OSA by the STOP-BANG questionnaire but not by the STOP
51
52
53
54
55
56
57
58
59
60
questionnaire.

1
2
3
4
5 For the AHI cut-point of ≥ 5 , the Berlin, STOP, and STOP-BANG questionnaires had high
6 sensitivities, moderate positive predictive values (PPV) and poor specificities and negative
7 predictive values (NPV), for prediction of SDB. The STOP-BANG questionnaire performed
8 best with an overall accuracy of 79%. For the AHI cut-point of ≥ 15 , the Berlin questionnaire
9 had high sensitivity, but otherwise performed poorly. The STOP and STOP-BANG
10 questionnaires had high sensitivities and NPVs. Again, the STOP-BANG questionnaire
11 performed best, but with a low overall accuracy of 56%. The low negative likelihood ratios
12 for the STOP and STOP-BANG questionnaires at both cut-points indicate that these
13 questionnaires have value in excluding disease. As shown in table 4, the cut-points for
14 STOP-BANG score that were associated with best overall accuracy were ≥ 3 and ≥ 6 for
15 prediction of AHI ≥ 5 and ≥ 15 , respectively.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 *SDB versus no SDB: Predictors and a composite score (See Tables 5 and 6 and Figure 1)*

33
34 For the cut-point of AHI of ≥ 5 , univariate logistic regression showed significant associations
35 for age, gender, weight, neck circumference, witnessed apnoeas, triglycerides and
36 cholesterol/HDL ($p < 0.05$). For the cut-point of ≥ 15 , significant associations were found for
37 gender, weight, BMI, neck circumference, witnessed apnoeas, obesity, hypertension, FeNO
38 and cholesterol/HDL ($p < 0.05$). Multivariate logistic regression based on the significant
39 variables from univariate logistic regression showed that for both cut-points neck
40 circumference and witnessed apnoeas were independent predictors of SDB. For the cut-point
41 of AHI of ≥ 5 , in a model incorporating neck circumference and witnessed apnoeas, the
42 probability of SDB was 0.94 for individuals with neck circumference ≥ 17 in and witnessed
43 apnoeas (sensitivity 84%, overall accuracy 77%, ROC AUC 0.768, $p < 0.001$). For the cut-
44 point of AHI ≥ 15 , the probability of SDB was 0.69 for individuals with neck circumference
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ≥ 17 in and witnessed apnoeas (specificity 80%, overall accuracy 69%, ROC AUC 0.722,
4
5 $p < 0.001$).

9 10 **Discussion**

11 This is the first study to prospectively evaluate the utility of the Berlin, STOP and STOP-
12 BANG questionnaires in prediction of sleep disordered breathing in a population referred to a
13 tertiary sleep service for assessment of possible OSA. We found that in this population the
14 Berlin Questionnaire had no significant association with cut-points of ≥ 5 or ≥ 15 for AHI, but
15 that both the STOP and STOP-BANG scores were significantly associated with both cut-
16 points. The STOP-BANG Questionnaire had better performance for the prediction of OSA on
17 home sleep study, and different cut-points for STOP-BANG score could be selected
18 depending on preference to exclude SDB (score < 3) or predict SDB (score ≥ 6). In addition,
19 we found notable associations between sleep study results and several patient characteristics.
20 In particular, neck circumference and witnessed apnoeas were found to be independent
21 predictors of SDB in our population.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In our study, the Berlin Questionnaire was almost ubiquitously positive (116 of 125
participants had a positive result) and the positivity rate did not differ between those with and
without SDB. This was expected as this questionnaire was designed for primary care
assessment and our study population consisted of individuals referred from primary care with
symptoms suggestive of SDB. Our results indicate that the Berlin Questionnaire is not useful
in the prediction of SDB in the sleep clinic referral population and this is consistent with
previous reports.⁽¹⁹⁾ However, the high sensitivities obtained for both AHI cut-points
support previous findings that the Berlin Questionnaire may have a role as a “rule-out”

1
2
3 measurement in the primary care or screening setting(15, 17, 20, 24), though there have been
4
5 some conflicting results, suggesting it does not have adequate discriminatory power.(16, 22)
6
7

8
9
10 In our study Epworth Sleepiness Scale data indicated that two thirds of participants had
11
12 excessive daytime somnolence (ESS ≥ 11), however scores were similar in individuals with or
13
14 without SDB. Therefore, at least in the sleep clinic population, the ESS does not have utility
15
16 in the prediction of SDB. Nevertheless, it may be clinically useful in other respects - perhaps
17
18 modified and/or combined with other structured questions, including those highlighted in this
19
20 study - in prediction of compliance with and benefit from OSA treatment in patients with any
21
22 degree of SDB. Exhaled nitric oxide levels were not significantly different between
23
24 individuals with or without SDB whether defined by an AHI cut-point of ≥ 5 or ≥ 15 . There is
25
26 conflicting data in the literature regarding whether $F_{E}NO$ is associated with SDB,(29-32)
27
28 however our results suggest that it does not have utility in prediction of SDB; further work is
29
30 required to clarify this.
31
32
33
34
35

36 We found that both the STOP and STOP-BANG questionnaires have utility in the prediction
37
38 of SDB in the sleep clinic population, and that STOP-BANG was superior, with higher
39
40 overall predictive accuracy. The STOP and STOP-BANG Questionnaires were developed
41
42 and validated in a surgical population using in-laboratory polysomnography(23) and have
43
44 subsequently been studied in a cardiovascular disease population.(25) Our results are in
45
46 agreement with these two earlier studies as regards the increased predictive value of STOP-
47
48 BANG over STOP. In contrast to these earlier studies, however, we found sensitivities to be
49
50 higher and specificities to be lower for both cut-points of AHI. This is as expected given that
51
52 we were studying a symptomatic cohort referred to a sleep clinic, rather than a screening
53
54 population, and this is also a desirable outcome for these questionnaires in situations where
55
56
57
58
59
60

1
2
3 missing even mild OSA would be undesirable. The negative likelihood ratios of <0.2
4
5 obtained for STOP and STOP-BANG indicate that these questionnaires are likely most useful
6
7 for predicting low risk of confirming SDB: these may be of future value in combination in the
8
9 primary care setting, perhaps combined with screening sleep studies, to determine
10
11 requirement for sleep clinic review and detailed polygraphy.
12
13

14
15
16 At the AHI cut-point of ≥ 15 , STOP-BANG had sensitivity and negative predictive value of
17
18 100%, and since this is the standard cut-point conventionally used to determine need for
19
20 CPAP,(28) we suggest that the STOP-BANG questionnaire is the preferred tool for prediction
21
22 of SDB in the sleep clinic setting of those currently available. STOP-BANG, perhaps with
23
24 modifications, seems worthwhile for further exploration for the prediction of sleep study
25
26 findings in a larger cohort and, more importantly, prediction of clinical outcomes including
27
28 treatment success in symptomatic and screening populations.
29
30
31

32
33
34 The original STOP-BANG questionnaire uses a cut-point of ≥ 3 to predict SDB.(23)
35
36 However, in our study we show that different cut-points can be selected depending on the
37
38 preference to rule-in or rule-out SDB. A score of ≥ 3 had the highest overall accuracy and a
39
40 sensitivity of 0.93 for the AHI cut-point of ≥ 5 , whereas a score of ≥ 6 had the highest overall
41
42 accuracy and a specificity of 0.78 for the AHI cut-point of ≥ 15 . Two other studies have
43
44 examined the usefulness of different cut-points for STOP-BANG score.(33-34) In the obese,
45
46 a score of ≥ 3 was associated with a sensitivity of 0.90 for predicting an AHI >5 , whilst, a
47
48 score of ≥ 6 had a specificity of 0.88 for predicting an AHI >15 and similar results were
49
50 obtained in the morbidly obese(33) and in another surgical population.(34) Thus, in the sleep
51
52 clinic setting where the ultimate goal is to identify patients requiring CPAP, a higher cut-point
53
54
55
56
57
58
59
60

1
2
3 for STOP-BANG may be preferred whereas in a primary care setting where the priority is not
4
5 to miss disease a lower cut-point may be chosen.
6
7

8
9
10 The STOP-BANG questionnaire is, however, still an imperfect tool for prediction of results
11
12 on home polygraphy. Accordingly, the secondary objective of our study was to identify those
13
14 variables for inclusion, and how they should be weighted in a locally developed composite
15
16 score for future validation in the sleep clinic and potentially wider population. Univariate
17
18 analysis showed several significant, expected associations for both cut-points of AHI. Using
19
20 multivariate analysis, neck circumference ≥ 17 in and the presence of witnessed apnoeas were
21
22 independent predictors of SDB. Particularly when SDB was defined by an AHI cut-point of
23
24 ≥ 5 , the regression model derived indicated a high probability of SDB of 0.94 if both factors
25
26 were present. The STOP-BANG questionnaire, of course, includes both of these variables,
27
28 and it is possible that adjustment of the inclusion variables, or their weighting, might improve
29
30 its performance. In future work, we aim to validate a simple composite score based on these
31
32 two variables in a modification of the STOP-BANG Questionnaire, to determine utility for
33
34 predicting sleep study data and outcomes with treatment.
35
36
37
38
39

40
41 A possible limitation of our study was that SDB was characterised using home unattended
42
43 limited sleep studies rather than in-hospital attended full polysomnography. The latter is
44
45 considered the gold standard for diagnosis of SDB but is more expensive, less easily accessed
46
47 and potentially unrepresentative with sleep in an unfamiliar environment. Home unattended
48
49 and in-hospital attended sleep studies have previously been shown to produce similar results.
50
51 (35) Accordingly home testing with portable monitors is standard clinical practice in the UK,
52
53 and is now considered an acceptable method for diagnosis of OSA by the American Academy
54
55 of Sleep Medicine.(28) The sample size limits the conclusions that can be drawn from
56
57
58
59
60

1
2
3 multivariate analysis, however this was a secondary objective of the current study. It is
4 possible that variables predictive of SDB on univariate analysis in this cohort would have
5 been identified as independently predictive in multivariate models in a larger population. The
6 results of this study allow us, and potentially others, to focus future work to validate more
7 extensively the results obtained to date.
8
9
10
11
12

13
14
15
16 In conclusion, the Berlin Questionnaire was not useful in the prediction of SDB within our
17 sleep clinic population. The STOP-BANG questionnaire had superior predictive performance
18 to the STOP questionnaire at both cut-points of AHI (≥ 5 and ≥ 15). A STOP-BANG score of
19 ≥ 3 had the highest overall accuracy and a sensitivity of 0.93 for the prediction of an AHI ≥ 5 ,
20 whilst a score of ≥ 6 had the highest overall accuracy and a specificity of 0.78 for the
21 prediction of an AHI ≥ 15 . Future work will validate a composite score including neck
22 circumference ≥ 17 in and the presence of witnessed apnoeas for the prediction of SDB in the
23 sleep clinic referral population, with possibility then of evaluating in primary care and against
24 treatment outcomes, with our overall aim to provide required tools for use in expanded and
25 consolidated sleep services, given the obesity and OSA epidemics.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributorship Statement:

Douglas Cowan took a leading role in study protocol development, study document development, application for ethics approval, data collection, statistical analysis and paper writing.

Gwen Allardice provided statistical support and performed part of the statistical analysis.

Duncan MacFarlane, Darren Ramsay and Heather Ambler contributed to data collection, and carried out and scored sleep studies.

Stephen Banham contributed to study protocol development.

Eric Livingston contributed to study protocol development, study document development, application for ethics approval and paper writing.

Christopher Carlin contributed to study protocol development, data collection, statistical analysis and paper writing.

All authors approved the final draft before submission.

Christopher Carlin is responsible for the overall content as guarantor.

Competing Interest: None to declare.

Additional unpublished data from this study is available on request by email.

Funding: There was no funding for this study.

Data Sharing Statement: Additional unpublished data from this study is available on request by email.

This study was approved by the West of Scotland Regional Ethics Committee.

References

1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*. 1993;328(17):1230-5.
2. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. *Lancet*. 2013; published online August 6. DOI:10.1016/S0140-6736(13)60734-5.
3. McNicholas WT. Diagnosis of obstructive sleep apnea in adults. *Proc Am Thorac Soc*. 2008;5(2):154-60.
4. Lacasse Y, Godbout C, Series F. Health-related quality of life in obstructive sleep apnoea. *Eur Respir J*. 2002;19(3):499-503.
5. Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. *Thorax*. 2004;59(7):618-22.
6. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. *N Engl J Med*. 1999;340(11):847-51.
7. Robinson GV, Stradling JR, Davies RJ. Sleep . 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension. *Thorax*. 2004;59(12):1089-94.
8. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. *J Am Coll Cardiol*. 2003;41(9):1429-37.
9. Svatikova A, Wolk R, Gami AS, et al. Interactions between obstructive sleep apnea and the metabolic syndrome. *Curr Diab Rep*. 2005;5(1):53-8.
10. Meslier N, Gagnadoux F, Giraud P, et al. Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. *Eur Respir J*. 2003;22(1):156-60.
11. Young T, Evans L, Finn L, et al. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. *Sleep*. 1997;20(9):705-6.
12. Heffner JE, Rozenfeld Y, Kai M, et al. Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. *Chest*. 2012;141(6):1414-21.
13. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. *Int J Pediatr Obes*. 2006;1(1):11-25.
14. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. *JAMA*. 2002;288(14):1723-7.
15. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern Med*. 1999;131(7):485-91.
16. Sert Kuniyoshi FH, Zellmer MR, Calvin AD, et al. Diagnostic accuracy of the Berlin Questionnaire in detecting sleep-disordered breathing in patients with a recent myocardial infarction. *Chest*. 2011;140(5):1192-7.
17. Best MW, Fitzpatrick M, Milev R, et al. Utility of the Berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. *Sleep Breath*. 2013; published online April 12. DOI:10.1007/s11325-013-0827-2.
18. Kang K, Park KS, Kim JE, et al. Usefulness of the Berlin Questionnaire to identify patients at high risk for obstructive sleep apnea: a population-based door-to-door study. *Sleep Breath*. 2013;17(2):803-10.
19. Ahmadi N, Chung SA, Gibbs A, et al. The Berlin questionnaire for sleep apnea in a sleep clinic population: relationship to polysomnographic measurement of respiratory disturbance. *Sleep Breath*. 2008;12(1):39-45.
20. Bouloukaki I, Komninos ID, Mermigkis C, et al. Translation and validation of Berlin questionnaire in primary health care in Greece. *BMC Pulm Med*. 2013;13:6.

21. Saleh AB, Ahmad MA, Awadalla NJ. Development of Arabic version of Berlin questionnaire to identify obstructive sleep apnea at risk patients. *Ann Thorac Med*. 2011;6(4):212-6.
22. Sforza E, Chouchou F, Pichot V, et al. Is the Berlin questionnaire a useful tool to diagnose obstructive sleep apnea in the elderly? *Sleep Med*. 2011;12(2):142-6.
23. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology*. 2008;108(5):812-21.
24. Chung F, Yegneswaran B, Liao P, et al. Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. *Anesthesiology*. 2008;108(5):822-30.
25. Silva GE, Vana KD, Goodwin JL, et al. Identification of patients with sleep disordered breathing: comparing the four-variable screening tool, STOP, STOP-Bang, and Epworth Sleepiness Scales. *J Clin Sleep Med*. 2011;7(5):467-72.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep*. 1991;14(6):540-5.
27. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. *Sleep*. 1999;22(5):667-89.
28. Epstein LJ, Kristo D, Strollo PJ, Jr., et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med*. 2009;5(3):263-76.
29. Chua AP, Aboussouan LS, Minai OA, et al. Long-term continuous positive airway pressure therapy normalizes high exhaled nitric oxide levels in obstructive sleep apnea. *J Clin Sleep Med*. 2013;9(6):529-35.
30. Fortuna AM, Miralda R, Calaf N, et al. Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome. *Respir Med*. 2011;105(4):630-6.
31. Depalo A, Carpagnano GE, Spanevello A, et al. Exhaled NO and iNOS expression in sputum cells of healthy, obese and OSA subjects. *J Intern Med*. 2008;263(1):70-8.
32. Agustí AG, Barbe F, Togo B. Exhaled nitric oxide in patients with sleep apnea. *Sleep*. 1999;22(2):231-5.
33. Chung F, Yang Y, Liao P. Predictive Performance of the STOP-Bang Score for Identifying Obstructive Sleep Apnea in Obese Patients. *Obes Surg*. 2013; published online June 19. DOI:10.1007/s11695-013-1006-z.
34. Chung F, Subramanyam R, Liao P, et al. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. *Br J Anaesth*. 2012;108(5):768-75.
35. Iber C, Redline S, Kaplan Gilpin AM, et al. Polysomnography performed in the unattended home versus the attended laboratory setting--Sleep Heart Health Study methodology. *Sleep*. 2004;27(3):536-40.

Table 1: Comparison of patient characteristics including anthropometric measurements, co-morbidities, symptoms, inflammatory markers, lipid profile and oximetry between groups without and with SDB as defined by AHI <5 events/hour and ≥ 15 events/hour.

	<i>AHI<5</i>	<i>AHI\geq5</i>	<i>p</i>	<i>AHI<15</i>	<i>AHI\geq15</i>	<i>P</i>
<i>Male gender</i>	15/32 (47%)	67/97 (69%)	0.034	38/73 (52%)	44/56 (79%)	0.003
<i>Age (yrs)</i>	44 (12)	51 (11)	0.004	48 (13)	51 (9)	0.103
<i>Weight (kg)</i>	89 (19)	101 (22)	0.022	92 (21)	107 (20)	0.001
<i>BMI (kg/m²)</i>	31 (28-36)	33 (29-40)	0.118	31 (27-36)	34 (31-41)	0.009
<i>Obesity (BMI\geq30 kg/m²)</i>	18/28 (64%)	61/85 (72%)	0.482	38/63 (60%)	41/50 (82%)	0.014
<i>Neck circumference (in)</i>	15 (2)	17(2)	<0.001	16 (2)	17 (1)	<0.001
<i>Neck circumference \geq17in</i>	4/22 (18%)	45/76 (59%)	0.001	18/54 (33%)	31/44 (70%)	<0.001
<i>Mallampatti</i>	2 (1)	2 (1)	0.192	2 (1)	2 (1)	0.900
<i>SBP (mmHg)</i>	134 (17)	136 (16)	0.480	134 (15)	138 (18)	0.194
<i>DBP (mmHg)</i>	82 (11)	83 (9)	0.528	81 (10)	85 (10)	0.086
<i>Diabetes</i>	2/32 (6%)	6/97 (6%)	1.000	4/73 (5%)	4/56 (7%)	0.727
<i>Hypertension</i>	7/32 (22%)	36/97 (37%)	0.134	18/73 (25%)	25/56 (45%)	0.024
<i>Hyperlipidaemia</i>	2/32 (6%)	18/97 (19%)	0.156	10/73 (14%)	10/56 (18%)	0.625
<i>Loud snorer</i>	28/32 (88%)	92/97 (95%)	0.224	65/73 (89%)	55/56 (98%)	0.077
<i>Witnessed apnoeas</i>	15/32 (47%)	72/97 (74%)	0.008	40/73 (55%)	47/56 (84%)	<0.001
<i>Nocturia*</i>	11/32 (34%)	38/97 (39%)	0.679	26/73 (36%)	23/56 (41%)	0.585
<i>Nocturnal wakenings*</i>	18/32 (56%)	65/97 (67%)	0.293	46/73 (63%)	37/56 (66%)	0.853
<i>Nocturnal choking</i>	15/32 (47%)	35/97 (36%)	0.301	28/73 (38%)	22/56 (39%)	1.000
<i>Nocturnal gasping</i>	11/32 (34%)	38/97 (39%)	0.679	26/73 (36%)	23/56 (41%)	0.585
<i>F_eNO (ppb)</i>	15 (12-25)	18 (12-26)	0.595	15 (11-24)	19 (12-27)	0.050
<i>Cholesterol (mmol/L)</i>	5.2 (1.1)	5.4 (1.0)	0.431	5.3 (1.1)	5.4 (0.9)	0.674
<i>HDL cholesterol (mmol/L)</i>	1.3 (1.0-1.5)	1.1 (1.0-1.3)	0.008	1.2 (1.0-1.4)	1.1 (1.0-1.2)	0.016
<i>Triglycerides (mmol/L)</i>	1.9 (1.0-2.5)	2.2 (1.5-3.2)	0.015	1.9 (1.3-2.9)	2.3 (1.6-3.2)	0.042
<i>Cholesterol/HDL</i>	4.1 (3.3-5.0)	4.7 (3.8-5.7)	0.011	4.3 (3.5-5.6)	4.8 (4.0-5.8)	0.022
<i>HbA1c (mmol/mol)</i>	34 (32-37)	38 (36-41)	0.001	36 (33-39)	38 (36-42)	0.002
<i>CRP</i>	3.0 (1.2-8.5)	3.8 (1.4-7.5)	0.608	3.0 (1.3-7.6)	4.3 (1.4-8.6)	0.173

Legend for Table 1: Data presented as mean (standard deviation), median (interquartile

range) or proportion (percentage) as appropriate. Significant differences in bold. * ≥ 2 /night.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; F_eNO, fraction of exhaled nitric oxide; HDL, high density lipoprotein; HbA1c, glycated haemoglobin; CRP, C-reactive protein; ODI, oxygen desaturation index; SpO₂, oxygen saturation; SpO₂ t<90, duration of time for which oxygen saturation less than 90%.

Table 2: Comparison of results of Epworth Sleepiness Scale (ESS) and Berlin, STOP and STOP-BANG Questionnaires between groups without and with SDB as defined by AHI <5 events/hour and ≥ 15 events/hour.

	<i>AHI</i> <5	<i>AHI</i> \geq 5	<i>p</i>	<i>AHI</i> <15	<i>AHI</i> \geq 15	<i>p</i>
<i>ESS score</i>	13 (8-16)	13 (7-17)	0.845	13 (7-16)	13 (9-18)	0.476
<i>ESS +ve ($\geq 11/24$)</i>	17/28 (61%)	63/92 (68%)	0.496	42/66 (64%)	38/54 (70%)	0.560
<i>Berlin +ve</i>	29/31 (94%)	87/94 (93%)	1.000	65/71 (92%)	51/54 (94%)	0.731
<i>STOP score</i>	2.5 (2-3)	3 (2-3)	0.011	3 (2-3)	3 (3-3.5)	<0.001
<i>STOP +ve ($\geq 2/4$)</i>	27/32 (84%)	93/96 (97%)	0.023	66/73 (90%)	54/55 (98%)	0.137
<i>STOP-BANG score</i>	4 (2-5)	5 (5-6)	<0.001	5 (2-5)	6 (5-6)	<0.001
<i>STOP-BANG +ve ($\geq 3/8$)</i>	21/30 (70%)	88/93 (95%)	<0.001	54/68 (79%)	55/55 (100%)	<0.001

Legend for Table 2: Data presented as median (interquartile range) or proportion (percentage)

as appropriate. Significant differences in bold.

Table 3: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), likelihood ratios positive (LR+), likelihood ratios negative (LR-), and overall accuracies of the Berlin, STOP and STOP-BANG Questionnaires for prediction of significant SDB as defined by: A: AHI \geq 5 events/hour; B: AHI \geq 15 events/hour.

A: Cut-point = AHI \geq 5 events/hour

	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
<i>Berlin</i>	0.93 (0.85-0.97)	0.06 (0.01-0.21)	0.75 (0.66-0.83)	0.22 (0.03-0.60)	0.99	1.15	71%
<i>STOP</i>	0.97 (0.91-0.99)	0.16 (0.05-0.33)	0.78 (0.69-0.85)	0.62 (0.24-0.91)	1.15	0.20	77%
<i>STOP-BANG</i>	0.95 (0.88-0.98)	0.30 (0.15-0.49)	0.81 (0.72-0.88)	0.64 (0.35-0.87)	1.35	0.18	79%

B: Cut-point = AHI \geq 15 events/hour

	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
<i>Berlin</i>	0.94 (0.85-0.99)	0.08 (0.03-0.17)	0.44 (0.35-0.53)	0.67 (0.30-0.92)	1.03	0.66	46%
<i>STOP</i>	0.98 (0.90-1.00)	0.10 (0.04-0.19)	0.45 (0.36-0.54)	0.88 (0.47-1.00)	1.09	0.19	48%
<i>STOP-BANG</i>	1.00 (0.94-1.00)	0.21 (0.12-0.32)	0.50 (0.41-0.60)	1.00 (0.77-1.00)	1.26	0.00	56%

Legend for Table 3: Data presented with 95% confidence intervals.

Table 4: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), likelihood ratios positive (LR+), likelihood ratios negative (LR-), and overall accuracies of different cut-points of the STOP-BANG questionnaire for prediction of significant SDB as defined by: A: AHI ≥ 5 events/hour; B: AHI ≥ 15 events/hour.

A: Cut-point = AHI ≥ 5 events/hour

<i>STOP-BANG cut-point (/8)</i>	<i>Proportion +ve SB</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
≥ 2	92/96	0.99 (0.92-1.00)	0.12 (0.03-0.32)	0.77 (0.67-0.85)	0.75 (0.19-0.99)	1.13	0.11	77%
≥ 3	82/96	0.93 (0.84-0.98)	0.38 (0.19-0.59)	0.82 (0.72-0.89)	0.64 (0.35-0.87)	1.49	0.18	79%
≥ 4	79/96	0.90 (0.81-0.96)	0.42 (0.22-0.63)	0.82 (0.72-0.90)	0.59 (0.33-0.82)	1.55	0.23	78%
≥ 5	67/96	0.81 (0.70-0.89)	0.62 (0.41-0.81)	0.87 (0.76-0.94)	0.52 (0.32-0.71)	2.15	0.31	76%
≥ 6	38/96	0.46 (0.34-0.58)	0.79 (0.58-0.93)	0.87 (0.72-0.96)	0.33 (0.21-0.46)	2.20	0.68	54%
≥ 7	15/96	0.18 (0.10-0.29)	0.92 (0.73-0.99)	0.87 (0.60-0.98)	0.27 (0.18-0.38)	2.17	0.89	36%
8	5/96	0.07 (0.02-0.15)	1.00 (0.86-1.00)	1.00 (0.48-1.00)	0.26 (0.18-0.37)	-	0.93	30%

B: Cut-point = AHI ≥ 15 events/hour

<i>STOP-BANG cut-point (/8)</i>	<i>Proportion +ve SB</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
≥ 2	92/96	1.00 (0.91-1.00)	0.07 (0.02-0.18)	0.45 (0.34-0.55)	1.00 (0.40-1.00)	1.08	0	47%
≥ 3	82/96	1.00 (0.91-1.00)	0.25 (0.15-0.39)	0.50 (0.39-0.61)	1.00 (0.77-1.00)	1.34	0	57%
≥ 4	79/96	1.00 (0.91-1.00)	0.31 (0.19-0.45)	0.52 (0.40-0.63)	1.00 (0.80-1.00)	1.45	0	60%
≥ 5	67/96	0.93 (0.80-0.98)	0.47 (0.34-0.61)	0.57 (0.44-0.69)	0.90 (0.73-0.98)	1.76	0.15	67%
≥ 6	38/96	0.63 (0.47-0.78)	0.78 (0.65-0.88)	0.68 (0.51-0.82)	0.74 (0.61-0.85)	2.91	0.47	72%
≥ 7	15/96	0.22 (0.11-0.38)	0.89 (0.78-0.96)	0.60 (0.32-0.84)	0.60 (0.49-0.71)	2.01	0.88	60%
8	5/96	0.10 (0.03-0.23)	0.98 (0.90-1.00)	0.80 (0.28-0.99)	0.59 (0.48-0.70)	5.36	0.92	60%

Legend for Table 4: Data presented with 95% confidence intervals. Abbreviations: SB,

STOP-BANG.

Table 5: Probabilities of SDB using a composite score based on neck circumference (≥ 17 in or < 17 in) and presence (1) or absence (0) of witnessed apnoeas derived from logistic regression models. SDB defined by: A: AHI ≥ 5 events/hour; B: AHI ≥ 15 events/hour.

A: Cut-point = AHI ≥ 5 events/hour

<i>Neck Circumference (in)</i>	<i>Witnessed Apnoeas</i>	
	<i>0</i>	<i>1</i>
<i><17</i>	0.47	0.75
<i>≥ 17</i>	0.83	0.94

B: Cut-point = AHI ≥ 15 events/hour

<i>Neck Circumference (in)</i>	<i>Witnessed Apnoeas</i>	
	<i>0</i>	<i>1</i>
<i><17</i>	0.17	0.40
<i>≥ 17</i>	0.40	0.69

Table 6: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), and overall accuracies of logistic models for prediction of SDB as defined by:

A: AHI ≥ 5 events/hour; predict SDB *unless* neck < 17 in *and* witnessed apnoeas absent; B:

AHI ≥ 15 events/hour; predict SDB *only if* neck ≥ 17 in *and* witnessed apnoeas present.

<i>Model</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>Accuracy</i>
A	0.84 (0.75-0.91)	0.54 (0.34-0.72)	0.85 (0.76-0.92)	0.52 (0.32-0.71)	77%
B	0.56 (0.41-0.70)	0.80 (0.68-0.89)	0.69 (0.53-0.82)	0.69 (0.57-0.79)	69%

Legend for Table 6: Data presented with 95% confidence intervals.


1
2
3 **Figure 1:** ROC curves of logistic models for prediction of SDB as defined by: A: AHI ≥ 5
4 events/hour; predict SDB *unless* neck < 17 in *and* witnessed apnoeas absent; B: AHI ≥ 15
5 events/hour; predict SDB *only if* neck ≥ 17 in *and* witnessed apnoeas present.
6
7
8

9
10 Model A:

11
12 Model B:
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



140x102mm (300 x 300 DPI)

view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



140x102mm (300 x 300 DPI)

view only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	

Results		Page	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,18
		(b) Indicate number of participants with missing data for each variable of interest	19
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9,10,19-23
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	20-21
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10,22-23
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.



Predicting sleep disordered breathing in outpatients with suspected OSA

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004519.R1
Article Type:	Research
Date Submitted by the Author:	07-Feb-2014
Complete List of Authors:	Cowan, Douglas; Glasgow Royal Infirmary, North Glasgow Sleep Service, Respiratory Department Allardice, Gwen; University of Glasgow, West of Scotland Cancer Surveillance Unit MacFarlane, Duncan; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Ramsay, Darren; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Ambler, Heather; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Banham, Stephen; Gartnavel General Hospital, North Glasgow Sleep Service, Respiratory Department Livingston, Eric; Glasgow Royal Infirmary, North Glasgow Sleep Service, Respiratory Department Carlin, Christopher; Gartnavel General Hospital, Sleep and Breathing Support
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	Sleep medicine < ANAESTHETICS, SLEEP MEDICINE, Adult thoracic medicine < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

1
2
3 **Predicting sleep disordered breathing in outpatients with**
4
5
6 **suspected OSA**
7
8
9

10
11 **¹Douglas C. Cowan BMedSci, MBChB, MRCP, PhD; ²Gwen Allardice BSc,**
12
13 **MSc, PhD; ¹Duncan MacFarlane BSc; ¹Darren Ramsay BSc; ¹Heather**
14 **Ambler; ¹Stephen Banham MBChB, MD, FRCP; ¹Eric Livingston BSc,**
15 **MBChB, MD, FRCP; ¹Christopher Carlin BSc, MBChB, MRCP, PhD.**
16
17
18
19
20
21
22
23

24 **¹North Glasgow Sleep Service, Gartnavel General Hospital and Glasgow Royal**
25 **Infirmery, Glasgow, UK;**
26
27
28

29 **²West of Scotland Cancer Surveillance Unit, University of Glasgow, Glasgow,**
30 **UK.**
31
32
33
34
35
36
37

38 ***Address for correspondence:***

39 Dr Douglas C Cowan,
40
41 Respiratory Department,
42
43 Glasgow Royal Infirmery,
44
45 16 Alexander Parade.
46
47
48 Glasgow,
49
50 UK,
51
52 G31 2ER
53
54
55

56
57 Tel: +44 141 211 3482
58
59
60

1
2
3 e-mail: douglas.cowan@otago.ac.nz
4

5 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive
6 licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its
7 Licensees to permit this article (if accepted) to be published in Thorax and any other BMJPGJ products to exploit all
8 subsidiary rights, as set out in our licence
9

10
11 **Running title:** Prediction of Sleep Disordered Breathing
12

13
14 **Word count:** 3298
15

16 **Key words:** Obstructive Sleep Apnoea, Sleep Disordered Breathing, Berlin Questionnaire,
17 STOP-BANG questionnaire, prediction
18

19
20 Competing Interest: None to declare.
21

22
23 Additional unpublished data from this study is available on request by email.
24

25
26 There was no funding for this study.
27

28
29 This study was approved by the West of Scotland Regional Ethics Committee.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background: Validated predictors of sleep disordered breathing (SDB) are required to streamline sleep services in the face of the obesity epidemic. Berlin, STOP and STOP-BANG questionnaires are useful in other settings, but their ability to predict obstructive sleep apnoea (OSA) in the sleep clinic population is unknown. We considered the utility of these questionnaires, other patient characteristics, co-morbidities, Epworth Sleepiness Scale (ESS), exhaled nitric oxide (F_ENO) and blood markers for the prediction of SDB on limited polygraphy.

Methods: Data was obtained on 129 patients referred with possible OSA. We selected cut-points of apnoea hypopnoea index (AHI) of ≥ 5 and ≥ 15 per hour from their home polygraphy and determined associations of these with individual symptoms, questionnaire scores and other results. ROC analysis, univariate and multivariate logistic regression were used to explore these.

Results: AHI was ≥ 5 in 97 and ≥ 15 in 56 patients. STOP and STOP-BANG scores were associated with both AHI cut-points but results with ESS and Berlin Questionnaire scores were negative. STOP-BANG had a negative predictive value 1.00 (0.77-1.00) for an AHI ≥ 15 with a score ≥ 3 predicting AHI ≥ 5 with sensitivity 0.93 (95%CI 0.84-0.98) and accuracy 79%, whilst a score ≥ 6 predicted AHI ≥ 15 with specificity 0.78 (0.65-0.88) and accuracy 72%. Neck circumference ≥ 17 in and presence of witnessed apnoeas were independent predictors of SDB.

Conclusions: Both STOP and STOP-BANG questionnaires have utility for the prediction of SDB in the sleep clinic population. Modification of the STOP-BANG questionnaire merits further study in this and other patient groups.

(Word count 246)

1
2
3
4
5 Strengths and limitations of this study:
6

7 Strengths:
8

- 9
10 • This is the first study to prospectively evaluate the utility of the Berlin, STOP and
11 STOP-BANG questionnaires in the prediction of sleep disordered breathing in the
12 population referred to a sleep service for assessment of possible obstructive sleep
13 apnoea.
14
15 • This results of this study show that the STOP and STOP-BANG, but not the Berlin
16 questionnaire, have utility for prediction of sleep disordered breathing in the sleep
17 clinic population.
18
19
20
21
22
23
24

25 Weaknesses:
26

- 27
28 • This study uses home unattended limited sleep studies rather than in-hospital attended
29 full polysomnography, however this is considered standard clinical practice in the UK
30 and is considered an acceptable method for diagnosis of OSA by the American
31 Academy of Sleep Medicine.
32
33 • The sample size limits the conclusions that can be drawn from the multivariate
34 analysis, however this was a secondary objective of the study.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Obstructive sleep apnoea syndrome (OSAS) is common with prevalence of approximately 4% in middle-aged men and 2% in middle-aged women.(1) Frequent partial (hypopnoea) or complete (apnoea) upper airway collapse during sleep leads to oxygen desaturation, increased respiratory effort, arousal and sleep fragmentation.(2) Patients typically present with witnessed apnoeas, loud snoring and excessive daytime somnolence.(3) The syndrome is associated with impaired quality of life,(4) cognitive functioning and work performance,(5) and with increased risk of road traffic accidents.(6) OSAS is considered an independent risk factor for hypertension,(7) and has associations with coronary disease, stroke, heart failure, arrhythmias,(8) metabolic syndrome(9) and type 2 diabetes.(10)

Despite the substantial burden of this disease, it is under-recognised. One study estimated that 93% of females and 82% of males with moderate-severe OSAS were not clinically diagnosed,(11) and more recent data support this finding.(12) Sleep studies are required for OSAS diagnosis but are expensive and not widely available.(3) Given the recent increases in childhood(13) and adulthood obesity,(14) the workload for sleep clinics and sleep laboratories will increase. Predictors of sleep disordered breathing (SDB) are required to allow recognition of OSAS, and prioritisation of investigations.

Several questionnaires have been designed to screen for SDB in different populations. The Berlin Questionnaire was first validated in primary care against portable unattended sleep studies and a “high risk” score predicted a respiratory disturbance index >5 with sensitivity 0.86, specificity 0.77, positive predictive value 0.89 and likelihood ratio 3.79.(15) It’s utilisation in other populations has been assessed with variable success.(16-22) The STOP and STOP-BANG Questionnaires were originally validated in surgical patients using in-

1
2
3 hospital attended polysomnography.(23) For prediction of apnoea hypopnoea index (AHI)
4
5 greater than 5, 15 and 30, sensitivities for the STOP and STOP-BANG questionnaires were
6
7 65.6, 74.3 and 79.5%, and 83.9, 92.9 and 100%, respectively. The Berlin and STOP
8
9 questionnaires have been compared in a cohort of surgical patients (24) and the STOP and
10
11 STOP-BANG questionnaires have been compared in a large study involving several distinct
12
13 cardiovascular and respiratory disease cohorts.(25) No study has, however, compared these
14
15 screening tools in a sleep service-referred population. Finally, because of rising obesity rates,
16
17 there is the potential for increasing recognition of SDB in primary care and in the face of this
18
19 evolution in sleep clinic practice it is therefore necessary to update and re-evaluate established
20
21 assessment tools.
22
23
24

25
26
27 The objective of this study was, firstly, to compare utility of Berlin, STOP and STOP-BANG
28
29 questionnaires for prediction of SDB in a population referred to the sleep clinic for
30
31 assessment of possible OSA. Secondly, we sought to identify the most important variables
32
33 from these questionnaires and routine sleep clinic assessment that might be utilised in the
34
35 development of a composite predictive score for future use in this population.
36
37
38
39

40 **Methods**

41
42 This was a prospective observational study conducted May-December 2012. The protocol
43
44 was approved by the West of Scotland Research Ethics Committee. Study participants
45
46 received an information sheet and provided informed consent. .
47
48
49

50 *Participants*

51
52 Consecutive patients aged ≥ 16 years referred to the North Glasgow Sleep Service (a tertiary
53
54 centre) for assessment of possible OSA were invited to participate.
55
56
57
58
59
60

Measurements

Height, weight, body mass index (BMI), neck circumference, blood pressure and Epworth Sleepiness Scale (ESS)(26) were completed at the Sleep Clinic. Participants attended the Sleep Laboratory on a separate day so that a Sleep Physiologist could provide, and instruct on fitting, a sleep study device. On that occasion, relevant symptoms and co-morbidities were recorded, Mallampatti score was assessed, and the Berlin and STOP-BANG Questionnaires were completed. Blood samples including non-fasting lipid profile, glycated haemoglobin (HbA1c) and C-reactive protein (CRP) were taken. Two fractional exhaled nitric oxide (F_ENO) measurements were taken using the NIOX MINO[®] (Aerocrine, Solna, Sweden), and the mean calculated.

Sleep Studies

Unattended home limited polygraphy sleep studies were performed using the SOMNOmedics SOMNOscreen[™] kit (Randersacker, Germany) with channels that recorded body position, thoraco-abdominal movements, oronasal airflow, heart rate, pulse oximetry and snoring. Sleep study scoring by experienced Sleep Physiologists was in accordance with accepted guidelines.(27) An apnoea was defined as cessation of nasal flow for ≥ 10 seconds, whilst a hypnoea was defined as 50% reduction in nasal flow for ≥ 10 seconds, or lesser reduction in flow associated with oxygen desaturation of $\geq 4\%$.

The Epworth Sleepiness Scale (ESS), Berlin, STOP and STOP-BANG Questionnaires

The ESS is a validated measure of daytime sleepiness including eight questions, each with four possible responses, that assesses the likelihood of dozing in different situations; a score of $\geq 11/24$ denotes excessive daytime somnolence.(26) The Berlin Questionnaire includes

1
2
3 questions in three categories that relate firstly to snoring and witnessed apnoeas, secondly, to
4
5 tiredness, fatigue and sleepiness, and thirdly, to hypertension and obesity.(15) High risk of
6
7 OSA is defined by scoring positively in ≥ 2 categories. The STOP Questionnaire includes
8
9 four yes/no questions that relate to Snoring, Tiredness, Observed apnoeas and high blood
10
11 Pressure.(23) High risk of OSA is defined as a score of ≥ 2 . The STOP-BANG Questionnaire
12
13 includes four additional questions relating to BMI, Age, Neck circumference and Gender, and
14
15 high risk of OSA is defined as a score of ≥ 3 .(23)
16
17
18
19

20 21 *Statistical analyses*

22
23 Statistical analyses were carried out using GraphPad Prism 5, IBM SPSS Statistics 19 and
24
25 STATA 12. Normality of data was checked using D'Agostino & Pearson omnibus normality
26
27 test. A priori, two cut-points were chosen for AHI: ≥ 5 events/hour (the standard cut-point
28
29 for the diagnosis of OSA),(28) and ≥ 15 events/hour, to predict significant SDB (the standard
30
31 cut-point for initiating continuous positive airway pressure [CPAP] therapy).(28) Groups
32
33 were compared using unpaired t-tests, Mann-Whitney tests and Fisher's Exact tests as
34
35 appropriate. Sensitivities, specificities, positive and negative predictive values, positive and
36
37 negative likelihood ratios, and overall accuracies were calculated for each of the
38
39 questionnaires for prediction of SDB as defined by AHI cut-points of ≥ 5 and ≥ 15 .
40
41 Associations between individual variables and each of the cut-points for AHI were explored
42
43 using univariate and multivariate logistic regression. For multivariate analysis, in a few cases
44
45 where BMI was known but neck circumference was not known, a value for the neck
46
47 circumference was imputed using linear regression with BMI as the independent value. This
48
49 allowed for a dataset of 116 cases with all of the variables known or imputed to be built to
50
51 identify independent variables for inclusion in a composite score. Receiver operating
52
53 characteristic (ROC) curve analysis was used to assess predictive value and an area under the
54
55
56
57
58
59
60

1
2
3 curve (AUC) >0.7 was considered clinically significant. Data are presented as mean
4 (standard deviation), median (interquartile range) and proportion (percentage), unless stated
5 otherwise. A p value <0.05 was considered statistically significant.
6
7
8
9

10 11 12 **Results**

13
14 150 subjects participated in this study, of which 129 had adequate sleep study data and were
15 included in the analysis. AHI was ≥ 5 in 97/129 (75%) and ≥ 15 in 56/129 (43%). Overall, 82
16 (64%) were male, mean(SD) age was 49(11) years, and median(IQR) BMI was 32(29-39)
17
18 kg/m².
19
20
21
22
23
24

25 *Predicting SDB: Patient characteristics (See Table 1)*

26
27 An AHI <5 (“rule-out measurement”) was associated with female sex, younger age, lower
28 weight and neck circumference, less frequently reported witnessed apnoeas, higher high
29 density lipoprotein (HDL) cholesterol, and lower triglycerides, cholesterol/HDL and HbA1c.
30
31 An AHI ≥ 15 (“rule-in measurement”) was associated with male sex, obesity, higher weight,
32 BMI and neck circumference, more frequently reported hypertension and witnessed apnoeas,
33 lower HDL cholesterol, and higher triglycerides, cholesterol/HDL and HbA1c.
34
35
36
37
38
39
40
41
42

43 *Predicting SDB: ESS, Berlin, STOP and STOP-BANG (See Tables 2, 3 and 4)*

44
45 The ESS and Berlin questionnaire outcomes were not associated with either AHI cut-point.
46
47 An AHI <5 was associated with lower STOP and STOP-BANG scores, and fewer subjects
48 being classified as “high risk” for OSA by both STOP and STOP-BANG questionnaires. An
49 AHI ≥ 15 was associated with higher STOP and STOP-BANG scores and more subjects being
50 classified as “high risk” for OSA by the STOP-BANG questionnaire but not by the STOP
51
52
53
54
55
56
57
58
59
60
questionnaire.

1
2
3
4
5 For the AHI cut-point of ≥ 5 , the Berlin, STOP, and STOP-BANG questionnaires had high
6 sensitivities, moderate positive predictive values (PPV) and poor specificities and negative
7 predictive values (NPV), for prediction of SDB. The STOP-BANG questionnaire performed
8 best with an overall accuracy of 79%. For the AHI cut-point of ≥ 15 , the Berlin questionnaire
9 had high sensitivity, but otherwise performed poorly. The STOP and STOP-BANG
10 questionnaires had high sensitivities and NPVs. Again, the STOP-BANG questionnaire
11 performed best, but with a low overall accuracy of 56%. The low negative likelihood ratios
12 for the STOP and STOP-BANG questionnaires at both cut-points indicate that these
13 questionnaires have value in excluding disease. As shown in table 4, the cut-points for
14 STOP-BANG score that were associated with best overall accuracy were ≥ 3 and ≥ 6 for
15 prediction of AHI ≥ 5 and ≥ 15 , respectively.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31

32 *SDB versus no SDB: Predictors and a composite score (See Tables 5 and 6 and Figure 1)*

33
34 For the cut-point of AHI of ≥ 5 , univariate logistic regression showed significant associations
35 for age, gender, weight, neck circumference, witnessed apnoeas, triglycerides and
36 cholesterol/HDL ($p < 0.05$). For the cut-point of ≥ 15 , significant associations were found for
37 gender, weight, BMI, neck circumference, witnessed apnoeas, obesity, hypertension, FeNO
38 and cholesterol/HDL ($p < 0.05$). Multivariate logistic regression based on the significant
39 variables from univariate logistic regression showed that for both cut-points neck
40 circumference and witnessed apnoeas were independent predictors of SDB. For the cut-point
41 of AHI of ≥ 5 , in a model incorporating neck circumference and witnessed apnoeas, the
42 probability of SDB was 0.94 for individuals with neck circumference ≥ 17 in and witnessed
43 apnoeas (sensitivity 84%, overall accuracy 77%, ROC AUC 0.768, $p < 0.001$). For the cut-
44 point of AHI ≥ 15 , the probability of SDB was 0.69 for individuals with neck circumference
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 ≥ 17 in and witnessed apnoeas (specificity 80%, overall accuracy 69%, ROC AUC 0.722,
4
5 $p < 0.001$).

6 7 8 9 **Discussion**

10
11 This is the first study to prospectively evaluate the utility of the Berlin, STOP and STOP-
12
13 BANG questionnaires in prediction of sleep disordered breathing in a population referred to a
14
15 tertiary sleep service for assessment of possible OSA. We found that in this population the
16
17 Berlin Questionnaire had no significant association with cut-points of ≥ 5 or ≥ 15 for AHI, but
18
19 that both the STOP and STOP-BANG scores were significantly associated with both cut-
20
21 points. The STOP-BANG Questionnaire had better performance for the prediction of OSA on
22
23 home sleep study, and different cut-points for STOP-BANG score could be selected
24
25 depending on preference to exclude SDB (score < 3) or predict SDB (score ≥ 6). In addition,
26
27 we found notable associations between sleep study results and several patient characteristics.
28
29 In particular, neck circumference and witnessed apnoeas were found to be independent
30
31 predictors of SDB in our population.
32
33
34
35
36
37

38
39 In our study, the Berlin Questionnaire was almost ubiquitously positive (116 of 125
40
41 participants had a positive result) and the positivity rate did not differ between those with and
42
43 without SDB. This was expected as this questionnaire was designed for primary care
44
45 assessment and our study population consisted of individuals referred from primary care with
46
47 symptoms suggestive of SDB. Our results indicate that the Berlin Questionnaire is not useful
48
49 in the prediction of SDB in the sleep clinic referral population and this is consistent with
50
51 previous reports.⁽¹⁹⁾ The high sensitivities obtained for both AHI cut-points support
52
53 previous findings that the Berlin Questionnaire may have a role as a “rule-out” measurement
54
55
56
57
58
59
60

1
2
3 in the primary care or screening setting(15, 17, 20, 24), though there have been some
4
5 conflicting results, suggesting it does not have adequate discriminatory power.(16, 22)
6
7

8
9
10 In our study Epworth Sleepiness Scale data indicated that two thirds of participants had
11
12 excessive daytime somnolence (ESS ≥ 11), however scores were similar in individuals with or
13
14 without SDB. Therefore, at least in the sleep clinic population, the ESS is not useful for the
15
16 prediction of SDB. It may be of value,perhaps combined with other measures, including
17
18 those highlighted in this study, in prediction of compliance with and benefit from OSA
19
20 treatment. Further research is required to address this question. Exhaled nitric oxide levels
21
22 were not significantly different between individuals with or without SDB whether defined by
23
24 an AHI cut-point of ≥ 5 or ≥ 15 . There is conflicting data in the literature regarding whether
25
26 $F_{E}NO$ is associated with SDB,(29-32) however our results suggest that it does not have utility
27
28 in prediction of SDB; further work is required to clarify this.
29
30
31

32
33
34 We found that both the STOP and STOP-BANG questionnaires have utility in the prediction
35
36 of SDB in the sleep clinic population, and that STOP-BANG was superior, with higher
37
38 overall predictive accuracy. The STOP and STOP-BANG Questionnaires were developed
39
40 and validated in a surgical population using in-laboratory polysomnagraphy(23) and have
41
42 subsequently been studied in a cardiovascular disease population.(25) Our results are in
43
44 agreement with these two earlier studies as regards the increased predictive value of STOP-
45
46 BANG over STOP. In contrast to these earlier studies, however, we found sensitivities to be
47
48 higher and specificities to be lower for both cut-points of AHI. We suggest that of the two
49
50 AHI cut-points, ≥ 15 events/hr is the more important, being diagnostic of at least moderate
51
52 SDB and also an indication for CPAP treatment. At this cut-point, STOP and STOP-BANG
53
54 performed with high sensitivities and negative predictive values (STOP-BANG superior to
55
56
57
58
59
60

1
2
3 STOP) indicating that these questionnaires are more useful in excluding significant SDB.
4
5 This is further corroborated by the negative likelihood ratios of <0.2 obtained for STOP and
6
7 STOP-BANG that also indicate that these questionnaires are most useful in ruling out SDB.
8
9 The STOP-BANG may be of value in the primary care setting, perhaps combined with type
10
11 IV portable monitoring sleep studies, to determine requirement for sleep clinic review and
12
13 more detailed polygraphy.
14
15

16
17
18 At the AHI cut-point of ≥ 15 , STOP-BANG had sensitivity and negative predictive value of
19
20 100%, and since this is the standard cut-point conventionally used to determine need for
21
22 CPAP,(28) we suggest that the STOP-BANG questionnaire is the preferred tool for prediction
23
24 of SDB in the sleep clinic setting of those currently available. STOP-BANG, perhaps with
25
26 modifications, merits further evaluation for the prediction of SDB in the sleep clinic
27
28 population and, more importantly, its utility in prediction of clinical outcomes including
29
30 treatment success should be assessed.
31
32

33
34
35 The original STOP-BANG questionnaire uses a cut-point of ≥ 3 to predict SDB.(23)
36
37 However, in our study we show that different cut-points can be selected depending on the
38
39 preference to rule-in or rule-out SDB. A score of ≥ 3 had the highest overall accuracy and a
40
41 sensitivity of 0.93 for the AHI cut-point of ≥ 5 , whereas a score of ≥ 6 had the highest overall
42
43 accuracy and a specificity of 0.78 for the AHI cut-point of ≥ 15 . Two other studies have
44
45 examined the usefulness of different cut-points for STOP-BANG score.(33-34) In the obese,
46
47 a score of ≥ 3 was associated with a sensitivity of 0.90 for predicting an AHI >5 , whilst, a
48
49 score of ≥ 6 had a specificity of 0.88 for predicting an AHI >15 and similar results have been
50
51 obtained in the morbidly obese(33) and in a surgical population.(34) Thus, in the sleep clinic
52
53 setting where the ultimate goal is to identify patients requiring CPAP, a higher cut-point for
54
55
56
57
58
59
60

1
2
3 STOP-BANG may be preferred whereas in a primary care setting where the priority is not to
4
5 miss disease a lower cut-point may be chosen.
6
7

8
9
10 The STOP-BANG questionnaire is, however, still an imperfect tool for prediction of results
11
12 on home polygraphy. Accordingly, the secondary objective of our study was to identify
13
14 variables for inclusion in a locally developed composite score for future validation in the
15
16 sleep clinic and potentially wider population. Univariate analysis showed several significant,
17
18 expected associations for both cut-points of AHI. Using multivariate analysis, neck
19
20 circumference ≥ 17 in and the presence of witnessed apnoeas were independent predictors of
21
22 SDB. This is not a novel finding, but does support the robustness of our data. Particularly
23
24 when SDB was defined by an AHI cut-point of ≥ 5 , the regression model derived indicated a
25
26 high probability of SDB of 0.94 if both factors were present. The STOP-BANG
27
28 questionnaire, of course, includes both of these variables, and it is possible that adjustment of
29
30 the inclusion variables, or their weighting, might improve its performance. In future work, we
31
32 aim to validate a simple composite score based on these two variables in a modification of
33
34 STOP-BANG, to determine utility for predicting sleep study data and outcomes with
35
36 treatment.
37
38
39
40
41
42

43 Ultimately, a predictive tool that can be utilised in primary care is the goal. Our results
44
45 indicate low specificity of STOP-BANG, and therefore in its current form, if used in primary
46
47 care to identify patients requiring referral for further assessment, it is likely to result in a
48
49 significant percentage of patients being referred unnecessarily (false positives). It is hoped
50
51 that a modified STOP-BANG with improved specificity, while not compromising sensitivity,
52
53 may be developed that can be used safely in primary care for identification of patients
54
55 requiring referral to sleep services. Of upmost importance too is the prediction of treatment
56
57
58
59
60

1
2
3 outcome. Non-adherence to CPAP treatment occurs in between 46 and 83%.(35-36)
4
5 Prediction of poor adherence by STOP-BANG or other similar tools would allow greater
6
7 attention to interventions to improve adherence in patients more likely to default from
8
9 treatment. The authors are not aware of any studies investigating this question and future
10
11 research should explore this important issue.
12

13
14
15
16 A possible limitation of our study was that SDB was characterised using home unattended
17
18 limited sleep studies rather than in-hospital attended full polysomnography. The latter is
19
20 considered the gold standard for diagnosis of SDB but is more expensive, less easily accessed
21
22 and potentially unrepresentative with sleep in an unfamiliar environment. Home unattended
23
24 and in-hospital attended sleep studies have previously been shown to produce similar results.
25
26 (37) Accordingly home testing with portable monitors is standard clinical practice in the UK,
27
28 and is now considered an acceptable method for diagnosis of OSA by the American Academy
29
30 of Sleep Medicine.(28) The sample size limits the conclusions that can be drawn from
31
32 multivariate analysis, however this was a secondary objective of the current study. It is
33
34 possible that variables predictive of SDB on univariate analysis in this cohort would have
35
36 been identified as independently predictive in multivariate models in a larger population. The
37
38 results of this study allow us, and potentially others, to focus future work to validate more
39
40 extensively the results obtained to date. We chose AHI cut-points of ≥ 5 and ≥ 15 to define
41
42 significant SDB. This was based on the consensus guideline produced by the Adult
43
44 Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine that states
45
46 that diagnosis of OSA is based on a cut-point of >15 events/hr or >5 events/hr with relevant
47
48 symptoms, and that CPAP is indicated for treatment of moderate to severe OSA with ≥ 15
49
50 events/hr.(28) Although the cut-point of >30 events/hr is consistent with severe OSA we
51
52 suggest that this cut-point is less clinically relevant from a diagnostic perspective or from that
53
54
55
56
57
58
59
60

1
2
3 of determining treatment. Finally, due to the prospective design of our study, we cannot
4
5 comment on the relative value of other tools developed for prediction of OSA such as the
6
7 Sleep Apnea Clinical Score (38) and American Society of Anesthesiologists Checklist. (39)
8
9 To compare their utility with that of the Berlin, STOP and STOP-BANG questionnaires in the
10
11 population referred to the sleep service would require a further study.
12
13

14
15
16 In conclusion, the Berlin Questionnaire was not useful in the prediction of SDB within our
17
18 sleep clinic population. The STOP-BANG questionnaire had superior predictive performance
19
20 to the STOP questionnaire at both cut-points of AHI (≥ 5 and ≥ 15). A STOP-BANG score of
21
22 ≥ 3 had the highest overall accuracy and a sensitivity of 0.93 for the prediction of an AHI ≥ 5 ,
23
24 whilst a score of ≥ 6 had the highest overall accuracy and a specificity of 0.78 for the
25
26 prediction of an AHI ≥ 15 . Future work will validate a composite score including neck
27
28 circumference ≥ 17 in and the presence of witnessed apnoeas for the prediction of SDB in the
29
30 sleep clinic referral population. An optimised composite score could then be evaluated in
31
32 primary care and against treatment outcomes, with our overall aim being to provide required
33
34 tools for use in the expanded and consolidated sleep services that are now necessary given the
35
36 current obesity and OSA epidemics.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Funding:** There was no funding for this study.
5

6 This study was approved by the West of Scotland Regional Ethics Committee.
7
8
9

10
11 **Contributorship Statement:**

12 Douglas Cowan took a leading role in study protocol development, study document
13 development, application for ethics approval, data collection, statistical analysis and paper
14 writing.
15
16
17

18
19 Gwen Allardice provided statistical support and performed part of the statistical analysis.
20

21 Duncan MacFarlane, Darren Ramsay and Heather Ambler contributed to data collection, and
22 carried out and scored sleep studies.
23
24

25
26 Stephen Banham contributed to study protocol development.
27

28 Eric Livingston contributed to study protocol development, study document development,
29 application for ethics approval and paper writing.
30
31

32 Christopher Carlin contributed to study protocol development, data collection, statistical
33 analysis and paper writing.
34
35

36
37 All authors approved the final draft before submission.
38

39 Christopher Carlin is responsible for the overall content as guarantor.
40
41

42 **Competing Interest:** None to declare.
43

44 **Data Sharing Statement:** Additional unpublished data from this study is available on request
45 by email.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*. 1993 ;**328**:1230-5.
2. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. *Lancet*. 2013; published online DOI:10.1016/S0140-6736(13)60734-5.
3. McNicholas WT. Diagnosis of obstructive sleep apnea in adults. *Proc Am Thorac Soc*. 2008;**5**:154-60.
4. Lacasse Y, Godbout C, Series F. Health-related quality of life in obstructive sleep apnoea. *Eur Respir J*. 2002;**19**:499-503.
5. Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. *Thorax*. 2004;**59**:618-22.
6. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. *N Engl J Med*. 1999;**340**:847-51.
7. Robinson GV, Stradling JR, Davies RJ. Sleep . 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension. *Thorax*. 2004;**59**:1089-94.
8. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. *J Am Coll Cardiol*. 2003;**41**:1429-37.
9. Svatikova A, Wolk R, Gami AS, et al. Interactions between obstructive sleep apnea and the metabolic syndrome. *Curr Diab Rep*. 2005;**5**:53-8.
10. Meslier N, Gagnadoux F, Giraud P, et al. Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. *Eur Respir J*. 2003;**22**:156-60.
11. Young T, Evans L, Finn L, et al. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. *Sleep*. 1997;**20**:705-6.
12. Heffner JE, Rozenfeld Y, Kai M, et al. Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. *Chest*. 2012;**141**:1414-21.
13. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. *Int J Pediatr Obes*. 2006;**1**:11-25.
14. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. *JAMA*. 2002;**288**:1723-7.
15. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern Med*. 1999;**131**:485-91.
16. Sert Kuniyoshi FH, Zellmer MR, Calvin AD, et al. Diagnostic accuracy of the Berlin Questionnaire in detecting sleep-disordered breathing in patients with a recent myocardial infarction. *Chest*. 2011;**140**:1192-7.
17. Best MW, Fitzpatrick M, Milev R, et al. Utility of the Berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. *Sleep Breath*. 2013; published online DOI:10.1007/s11325-013-0827-2.
18. Kang K, Park KS, Kim JE, et al. Usefulness of the Berlin Questionnaire to identify patients at high risk for obstructive sleep apnea: a population-based door-to-door study. *Sleep Breath*. 2013;**17**:803-10.
19. Ahmadi N, Chung SA, Gibbs A, et al. The Berlin questionnaire for sleep apnea in a sleep clinic population: relationship to polysomnographic measurement of respiratory disturbance. *Sleep Breath*. 2008;**12**:39-45.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
20. Bouloukaki I, Komninos ID, Mermigkis C, et al. Translation and validation of Berlin questionnaire in primary health care in Greece. *BMC Pulm Med.* 2013;**13**:6.
21. Saleh AB, Ahmad MA, Awadalla NJ. Development of Arabic version of Berlin questionnaire to identify obstructive sleep apnea at risk patients. *Ann Thorac Med.* 2011;**6**:212-6.
22. Sforza E, Chouchou F, Pichot V, et al. Is the Berlin questionnaire a useful tool to diagnose obstructive sleep apnea in the elderly? *Sleep Med.* 2011;**12**:142-6.
23. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology.* 2008;**108**:812-21.
24. Chung F, Yegneswaran B, Liao P, et al. Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. *Anesthesiology.* 2008;**108**:822-30.
25. Silva GE, Vana KD, Goodwin JL, et al. Identification of patients with sleep disordered breathing: comparing the four-variable screening tool, STOP, STOP-Bang, and Epworth Sleepiness Scales. *J Clin Sleep Med.* 2011;**7**:467-72.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep.* 1991;**14**:540-5.
27. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. *Sleep.* 1999;**22**:667-89.
28. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med.* 2009;**5**:263-76.
29. Chua AP, Aboussouan LS, Minai OA, et al. Long-term continuous positive airway pressure therapy normalizes high exhaled nitric oxide levels in obstructive sleep apnea. *J Clin Sleep Med.* 2013;**9**:529-35.
30. Fortuna AM, Miralda R, Calaf N, et al. Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome. *Respir Med.* 2011;**105**:630-6.
31. Depalo A, Carpagnano GE, Spanevello A, et al. Exhaled NO and iNOS expression in sputum cells of healthy, obese and OSA subjects. *J Intern Med.* 2008;**263**:70-8.
32. Agustí AG, Barbe F, Togoeres B. Exhaled nitric oxide in patients with sleep apnea. *Sleep.* 1999;**22**:231-5.
33. Chung F, Yang Y, Liao P. Predictive Performance of the STOP-Bang Score for Identifying Obstructive Sleep Apnea in Obese Patients. *Obes Surg.* 2013; published online DOI:10.1007/s11695-013-1006-z.
34. Chung F, Subramanyam R, Liao P, et al. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. *Br J Anaesth.* 2012;**108**:768-75.
35. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. *Proc Am Thorac Soc.* 2008;**5**:173-8.
36. Wolkove N, Baltzan M, Kamel H, et al. Long-term compliance with continuous positive airway pressure in patients with obstructive sleep apnea. *Can Respir J.* 2008;**15**:365-9.
37. Iber C, Redline S, Kaplan Gilpin AM, et al. Polysomnography performed in the unattended home versus the attended laboratory setting--Sleep Heart Health Study methodology. *Sleep.* 2004;**27**:536-40.
38. Flemons WW, Whitelaw WA, Brant R, et al. Likelihood ratios for a sleep apnea clinical prediction rule. *Am J Respir Crit Care Med.* 1994;**150**:1279-85.
39. Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of

1
2
3 Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep
4 apnea. Anesthesiology. 2006 ;104:1081-93.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Comparison of patient characteristics including anthropometric measurements, co-morbidities, symptoms, inflammatory markers, lipid profile and oximetry between groups without and with SDB as defined by AHI <5 events/hour and ≥ 15 events/hour.

	<i>AHI<5</i>	<i>AHI\geq5</i>	<i>p</i>	<i>AHI<15</i>	<i>AHI\geq15</i>	<i>P</i>
<i>Male gender</i>	15/32 (47%)	67/97 (69%)	0.034	38/73 (52%)	44/56 (79%)	0.003
<i>Age (yrs)</i>	44 (12)	51 (11)	0.004	48 (13)	51 (9)	0.103
<i>Weight (kg)</i>	89 (19)	101 (22)	0.022	92 (21)	107 (20)	0.001
<i>BMI (kg/m²)</i>	31 (28-36)	33 (29-40)	0.118	31 (27-36)	34 (31-41)	0.009
<i>Obesity (BMI\geq30 kg/m²)</i>	18/28 (64%)	61/85 (72%)	0.482	38/63 (60%)	41/50 (82%)	0.014
<i>Neck circumference (in)</i>	15 (2)	17(2)	<0.001	16 (2)	17 (1)	<0.001
<i>Neck circumference \geq17in</i>	4/22 (18%)	45/76 (59%)	0.001	18/54 (33%)	31/44 (70%)	<0.001
<i>Mallampatti</i>	2 (1)	2 (1)	0.192	2 (1)	2 (1)	0.900
<i>SBP (mmHg)</i>	134 (17)	136 (16)	0.480	134 (15)	138 (18)	0.194
<i>DBP (mmHg)</i>	82 (11)	83 (9)	0.528	81 (10)	85 (10)	0.086
<i>Diabetes</i>	2/32 (6%)	6/97 (6%)	1.000	4/73 (5%)	4/56 (7%)	0.727
<i>Hypertension</i>	7/32 (22%)	36/97 (37%)	0.134	18/73 (25%)	25/56 (45%)	0.024
<i>Hyperlipidaemia</i>	2/32 (6%)	18/97 (19%)	0.156	10/73 (14%)	10/56 (18%)	0.625
<i>Loud snorer</i>	28/32 (88%)	92/97 (95%)	0.224	65/73 (89%)	55/56 (98%)	0.077
<i>Witnessed apnoeas</i>	15/32 (47%)	72/97 (74%)	0.008	40/73 (55%)	47/56 (84%)	<0.001
<i>Nocturia*</i>	11/32 (34%)	38/97 (39%)	0.679	26/73 (36%)	23/56 (41%)	0.585
<i>Nocturnal wakenings*</i>	18/32 (56%)	65/97 (67%)	0.293	46/73 (63%)	37/56 (66%)	0.853
<i>Nocturnal choking</i>	15/32 (47%)	35/97 (36%)	0.301	28/73 (38%)	22/56 (39%)	1.000
<i>Nocturnal gasping</i>	11/32 (34%)	38/97 (39%)	0.679	26/73 (36%)	23/56 (41%)	0.585
<i>F_eNO (ppb)</i>	15 (12-25)	18 (12-26)	0.595	15 (11-24)	19 (12-27)	0.050
<i>Cholesterol (mmol/L)</i>	5.2 (1.1)	5.4 (1.0)	0.431	5.3 (1.1)	5.4 (0.9)	0.674
<i>HDL cholesterol (mmol/L)</i>	1.3 (1.0-1.5)	1.1 (1.0-1.3)	0.008	1.2 (1.0-1.4)	1.1 (1.0-1.2)	0.016
<i>Triglycerides (mmol/L)</i>	1.9 (1.0-2.5)	2.2 (1.5-3.2)	0.015	1.9 (1.3-2.9)	2.3 (1.6-3.2)	0.042
<i>Cholesterol/HDL</i>	4.1 (3.3-5.0)	4.7 (3.8-5.7)	0.011	4.3 (3.5-5.6)	4.8 (4.0-5.8)	0.022
<i>HbA1c (mmol/mol)</i>	34 (32-37)	38 (36-41)	0.001	36 (33-39)	38 (36-42)	0.002
<i>CRP</i>	3.0 (1.2-8.5)	3.8 (1.4-7.5)	0.608	3.0 (1.3-7.6)	4.3 (1.4-8.6)	0.173

Legend for Table 1: Data presented as mean (standard deviation), median (interquartile

range) or proportion (percentage) as appropriate. Significant differences in bold. * ≥ 2 /night.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; F_eNO, fraction of exhaled nitric oxide; HDL, high density lipoprotein; HbA1c, glycated haemoglobin; CRP, C-reactive protein; ODI, oxygen desaturation index; SpO₂, oxygen saturation; SpO₂ t<90, duration of time for which oxygen saturation less than 90%.

Table 2: Comparison of results of Epworth Sleepiness Scale (ESS) and Berlin, STOP and STOP-BANG Questionnaires between groups without and with SDB as defined by AHI <5 events/hour and ≥ 15 events/hour.

	<i>AHI</i> <5	<i>AHI</i> \geq 5	<i>p</i>	<i>AHI</i> <15	<i>AHI</i> \geq 15	<i>p</i>
<i>ESS score</i>	13 (8-16)	13 (7-17)	0.845	13 (7-16)	13 (9-18)	0.476
<i>ESS +ve ($\geq 11/24$)</i>	17/28 (61%)	63/92 (68%)	0.496	42/66 (64%)	38/54 (70%)	0.560
<i>Berlin +ve</i>	29/31 (94%)	87/94 (93%)	1.000	65/71 (92%)	51/54 (94%)	0.731
<i>STOP score</i>	2.5 (2-3)	3 (2-3)	0.011	3 (2-3)	3 (3-3.5)	<0.001
<i>STOP +ve ($\geq 2/4$)</i>	27/32 (84%)	93/96 (97%)	0.023	66/73 (90%)	54/55 (98%)	0.137
<i>STOP-BANG score</i>	4 (2-5)	5 (5-6)	<0.001	5 (2-5)	6 (5-6)	<0.001
<i>STOP-BANG +ve ($\geq 3/8$)</i>	21/30 (70%)	88/93 (95%)	<0.001	54/68 (79%)	55/55 (100%)	<0.001

Legend for Table 2: Data presented as median (interquartile range) or proportion (percentage)

as appropriate. Significant differences in bold.

Table 3: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), likelihood ratios positive (LR+), likelihood ratios negative (LR-), and overall accuracies of the Berlin, STOP and STOP-BANG Questionnaires for prediction of significant SDB as defined by: A: AHI \geq 5 events/hour; B: AHI \geq 15 events/hour.

A: Cut-point = AHI \geq 5 events/hour

	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
<i>Berlin</i>	0.93 (0.85-0.97)	0.06 (0.01-0.21)	0.75 (0.66-0.83)	0.22 (0.03-0.60)	0.99	1.15	71%
<i>STOP</i>	0.97 (0.91-0.99)	0.16 (0.05-0.33)	0.78 (0.69-0.85)	0.62 (0.24-0.91)	1.15	0.20	77%
<i>STOP-BANG</i>	0.95 (0.88-0.98)	0.30 (0.15-0.49)	0.81 (0.72-0.88)	0.64 (0.35-0.87)	1.35	0.18	79%

B: Cut-point = AHI \geq 15 events/hour

	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
<i>Berlin</i>	0.94 (0.85-0.99)	0.08 (0.03-0.17)	0.44 (0.35-0.53)	0.67 (0.30-0.92)	1.03	0.66	46%
<i>STOP</i>	0.98 (0.90-1.00)	0.10 (0.04-0.19)	0.45 (0.36-0.54)	0.88 (0.47-1.00)	1.09	0.19	48%
<i>STOP-BANG</i>	1.00 (0.94-1.00)	0.21 (0.12-0.32)	0.50 (0.41-0.60)	1.00 (0.77-1.00)	1.26	0.00	56%

Legend for Table 3: Data presented with 95% confidence intervals.

Table 4: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), likelihood ratios positive (LR+), likelihood ratios negative (LR-), and overall accuracies of different cut-points of the STOP-BANG questionnaire for prediction of significant SDB as defined by: A: AHI ≥ 5 events/hour; B: AHI ≥ 15 events/hour.

A: Cut-point = AHI ≥ 5 events/hour

<i>STOP-BANG cut-point (/8)</i>	<i>Proportion +ve SB</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
≥ 2	92/96	0.99 (0.92-1.00)	0.12 (0.03-0.32)	0.77 (0.67-0.85)	0.75 (0.19-0.99)	1.13	0.11	77%
≥ 3	82/96	0.93 (0.84-0.98)	0.38 (0.19-0.59)	0.82 (0.72-0.89)	0.64 (0.35-0.87)	1.49	0.18	79%
≥ 4	79/96	0.90 (0.81-0.96)	0.42 (0.22-0.63)	0.82 (0.72-0.90)	0.59 (0.33-0.82)	1.55	0.23	78%
≥ 5	67/96	0.81 (0.70-0.89)	0.62 (0.41-0.81)	0.87 (0.76-0.94)	0.52 (0.32-0.71)	2.15	0.31	76%
≥ 6	38/96	0.46 (0.34-0.58)	0.79 (0.58-0.93)	0.87 (0.72-0.96)	0.33 (0.21-0.46)	2.20	0.68	54%
≥ 7	15/96	0.18 (0.10-0.29)	0.92 (0.73-0.99)	0.87 (0.60-0.98)	0.27 (0.18-0.38)	2.17	0.89	36%
8	5/96	0.07 (0.02-0.15)	1.00 (0.86-1.00)	1.00 (0.48-1.00)	0.26 (0.18-0.37)	-	0.93	30%

B: Cut-point = AHI ≥ 15 events/hour

<i>STOP-BANG cut-point (/8)</i>	<i>Proportion +ve SB</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
≥ 2	92/96	1.00 (0.91-1.00)	0.07 (0.02-0.18)	0.45 (0.34-0.55)	1.00 (0.40-1.00)	1.08	0	47%
≥ 3	82/96	1.00 (0.91-1.00)	0.25 (0.15-0.39)	0.50 (0.39-0.61)	1.00 (0.77-1.00)	1.34	0	57%
≥ 4	79/96	1.00 (0.91-1.00)	0.31 (0.19-0.45)	0.52 (0.40-0.63)	1.00 (0.80-1.00)	1.45	0	60%
≥ 5	67/96	0.93 (0.80-0.98)	0.47 (0.34-0.61)	0.57 (0.44-0.69)	0.90 (0.73-0.98)	1.76	0.15	67%
≥ 6	38/96	0.63 (0.47-0.78)	0.78 (0.65-0.88)	0.68 (0.51-0.82)	0.74 (0.61-0.85)	2.91	0.47	72%
≥ 7	15/96	0.22 (0.11-0.38)	0.89 (0.78-0.96)	0.60 (0.32-0.84)	0.60 (0.49-0.71)	2.01	0.88	60%
8	5/96	0.10 (0.03-0.23)	0.98 (0.90-1.00)	0.80 (0.28-0.99)	0.59 (0.48-0.70)	5.36	0.92	60%

Legend for Table 4: Data presented with 95% confidence intervals. Abbreviations: SB,

STOP-BANG.

Table 5: Probabilities of SDB using a composite score based on neck circumference (≥ 17 in or < 17 in) and presence (1) or absence (0) of witnessed apnoeas derived from logistic regression models. SDB defined by: A: AHI ≥ 5 events/hour; B: AHI ≥ 15 events/hour.

A: Cut-point = AHI ≥ 5 events/hour

<i>Neck Circumference (in)</i>	<i>Witnessed Apnoeas</i>	
	<i>0</i>	<i>1</i>
<i><17</i>	0.47	0.75
<i>≥ 17</i>	0.83	0.94

B: Cut-point = AHI ≥ 15 events/hour

<i>Neck Circumference (in)</i>	<i>Witnessed Apnoeas</i>	
	<i>0</i>	<i>1</i>
<i><17</i>	0.17	0.40
<i>≥ 17</i>	0.40	0.69

Table 6: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), and overall accuracies of logistic models for prediction of SDB as defined by:

A: AHI ≥ 5 events/hour; predict SDB *unless* neck < 17 in *and* witnessed apnoeas absent; B:

AHI ≥ 15 events/hour; predict SDB *only if* neck ≥ 17 in *and* witnessed apnoeas present.

<i>Model</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>Accuracy</i>
A	0.84 (0.75-0.91)	0.54 (0.34-0.72)	0.85 (0.76-0.92)	0.52 (0.32-0.71)	77%
B	0.56 (0.41-0.70)	0.80 (0.68-0.89)	0.69 (0.53-0.82)	0.69 (0.57-0.79)	69%

Legend for Table 6: Data presented with 95% confidence intervals.

1
2
3 **Figure 1:** ROC curves of logistic models for prediction of SDB as defined by: Model A: AHI
4 ≥ 5 events/hour; predict SDB *unless* neck < 17 in *and* witnessed apnoeas absent; Model B: AHI
5 ≥ 15 events/hour; predict SDB *only if* neck ≥ 17 in *and* witnessed apnoeas present.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **Predicting sleep disordered breathing in outpatients with**
4
5
6 **suspected OSA**
7
8
9

10
11 **¹Douglas C. Cowan BMedSci, MBChB, MRCP, PhD; ²Gwen Allardice BSc,**
12
13 **MSc, PhD; ¹Duncan MacFarlane BSc; ¹Darren Ramsay BSc; ¹Heather**
14 **Ambler; ¹Stephen Banham MBChB, MD, FRCP; ¹Eric Livingston BSc,**
15 **MBChB, MD, FRCP; ¹Christopher Carlin BSc, MBChB, MRCP, PhD.**
16
17
18
19
20
21
22
23

24 **¹North Glasgow Sleep Service, Gartnavel General Hospital and Glasgow Royal**
25 **Infirmery, Glasgow, UK;**
26
27
28

29 **²West of Scotland Cancer Surveillance Unit, University of Glasgow, Glasgow,**
30 **UK.**
31
32
33
34
35
36

37 ***Address for correspondence:***

38 Dr Douglas C Cowan,
39
40 Respiratory Department,
41
42 Glasgow Royal Infirmery,
43
44 16 Alexander Parade.
45
46
47 Glasgow,
48
49 UK,
50
51 G31 2ER
52
53
54

55
56
57 Tel: +44 141 211 3482
58
59
60

1
2
3 e-mail: douglas.cowan@otago.ac.nz
4

5 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive
6 licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its
7 Licensees to permit this article (if accepted) to be published in Thorax and any other BMJPGJL products to exploit all
8 subsidiary rights, as set out in our licence
9

10
11 **Running title:** Prediction of Sleep Disordered Breathing
12

13
14 **Word count:** 29973298
15

16 **Key words:** Obstructive Sleep Apnoea, Sleep Disordered Breathing, Berlin Questionnaire,
17 STOP-BANG questionnaire, prediction
18

19
20 Competing Interest: None to declare.
21

22
23 Additional unpublished data from this study is available on request by email.
24

25
26 There was no funding for this study.
27

28
29 This study was approved by the West of Scotland Regional Ethics Committee.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Background: Validated predictors of sleep disordered breathing (SDB) are required to streamline sleep services in the face of the obesity epidemic. Berlin, STOP and STOP-BANG questionnaires are useful in other settings, but their ability to predict obstructive sleep apnoea (OSA) in the sleep clinic population is unknown. We considered the utility of these questionnaires, other patient characteristics, co-morbidities, Epworth Sleepiness Scale (ESS), exhaled nitric oxide (F_ENO) and blood markers for the prediction of SDB on limited polygraphy.

Methods: Data was obtained on 129 patients referred with possible OSA. We selected cut-points of apnoea hypopnoea index (AHI) of ≥ 5 and ≥ 15 per hour from their home polygraphy and determined associations of these with individual symptoms, questionnaire scores and other results. ROC analysis, univariate and multivariate logistic regression were used to explore these.

Results: AHI was ≥ 5 in 97 and ≥ 15 in 56 patients. STOP and STOP-BANG scores were associated with both AHI cut-points but results with ESS and Berlin Questionnaire scores were negative. STOP-BANG had a negative predictive value 1.00 (0.77-1.00) for an AHI ≥ 15 with a score ≥ 3 predicting AHI ≥ 5 with sensitivity 0.93 (95%CI 0.84-0.98) and accuracy 79%, whilst a score ≥ 6 predicted AHI ≥ 15 with specificity 0.78 (0.65-0.88) and accuracy 72%. Neck circumference ≥ 17 in and presence of witnessed apnoeas were independent predictors of SDB.

Conclusions: Both STOP and STOP-BANG questionnaires have utility for the prediction of SDB in the sleep clinic population. Modification of the STOP-BANG questionnaire merits further study in this and other patient groups.

(Word count 246)

1
2
3
4
5 Strengths and limitations of this study:
6

7 Strengths:
8

- 9
- 10 • This is the first study to prospectively evaluate the utility of the Berlin, STOP and
11 STOP-BANG questionnaires in the prediction of sleep disordered breathing in the
12 population referred to a sleep service for assessment of possible obstructive sleep
13 apnoea.
14
 - 15 • This results of this study show that the STOP and STOP-BANG, but not the Berlin
16 questionnaire, have utility for prediction of sleep disordered breathing in the sleep
17 clinic population.
18
19
20
21
22
23
24

25 Weaknesses:
26

- 27 • This study uses home unattended limited sleep studies rather than in-hospital attended
28 full polysomnography, however this is considered standard clinical practice in the UK
29 and is considered an acceptable method for diagnosis of OSA by the American
30 Academy of Sleep Medicine.
31
32
- 33 • The sample size limits the conclusions that can be drawn from the multivariate
34 analysis, however this was a secondary objective of the study.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Obstructive sleep apnoea syndrome (OSAS) is common with prevalence of approximately 4% in middle-aged men and 2% in middle-aged women.(1) Frequent partial (hypopnoea) or complete (apnoea) upper airway collapse during sleep leads to oxygen desaturation, increased respiratory effort, arousal and sleep fragmentation.(2) Patients typically present with witnessed apnoeas, loud snoring and excessive daytime somnolence.(3) The syndrome is associated with impaired quality of life,(4) cognitive functioning and work performance,(5) and with increased risk of road traffic accidents.(6) OSAS is considered an independent risk factor for hypertension,(7) and has associations with coronary disease, stroke, heart failure, arrhythmias,(8) metabolic syndrome(9) and type 2 diabetes.(10)

Despite the substantial burden of this disease, it is under-recognised. One study estimated that 93% of females and 82% of males with moderate-severe OSAS were not clinically diagnosed,(11) and more recent data support this finding.(12) Sleep studies are required for OSAS diagnosis but are expensive and not widely available.(3) Given the recent increases in childhood(13) and adulthood obesity,(14) the workload for sleep clinics and sleep laboratories will increase. Predictors of sleep disordered breathing (SDB) are required to allow recognition of OSAS, and prioritisation of investigations.

Several questionnaires have been designed to screen for SDB in different populations. The Berlin Questionnaire was first validated in primary care against portable unattended sleep studies and a “high risk” score predicted a respiratory disturbance index >5 with sensitivity 0.86, specificity 0.77, positive predictive value 0.89 and likelihood ratio 3.79.(15) It’s utilisation in other populations has been assessed with variable success.(16-22) The STOP and STOP-BANG Questionnaires were originally validated in surgical patients using in-

1
2
3 hospital attended polysomnography.(23) For prediction of apnoea hypopnoea index (AHI)
4
5 greater than 5, 15 and 30, sensitivities for the STOP and STOP-BANG questionnaires were
6
7 65.6, 74.3 and 79.5%, and 83.9, 92.9 and 100%, respectively. The Berlin and STOP
8
9 questionnaires have been compared in a cohort of surgical patients (24) and the STOP and
10
11 STOP-BANG questionnaires have been compared in a large study involving several distinct
12
13 cardiovascular and respiratory disease cohorts.(25) No study has, however, compared these
14
15 screening tools in a sleep service-referred population. ~~Finally, because of~~ ~~Also, along with~~
16
17 ~~changes in the population (i.e. rising obesity rates,)~~ there is the potential for increasing
18
19 recognition of SDB in primary care; ~~so and in the face of this evolution in sleep clinic practice~~
20
21 it is therefore necessary to update and re-evaluate established assessment tools ~~in the face of~~
22
23 ~~the evolution in sleep clinic practice.~~
24
25
26
27
28

29
30 The objective of this study was, firstly, to compare utility of Berlin, STOP and STOP-BANG
31
32 questionnaires for prediction of SDB in a population referred to the sleep clinic for
33
34 assessment of possible OSA. Secondly, we sought to identify the most important variables
35
36 from these questionnaires and routine sleep clinic assessment that might be utilised in the
37
38 development of a composite predictive score for future use in this population.
39
40
41
42

43 **Methods**

44
45 This was a prospective observational study conducted May-December 2012. The protocol
46
47 was approved by the West of Scotland Research Ethics Committee. Study participants
48
49 received an information sheet and provided informed consent. .
50
51
52
53

54 *Participants*

55
56
57
58
59
60

1
2
3 Consecutive patients aged ≥ 16 years referred to the North Glasgow Sleep Service (a tertiary
4
5 centre) for assessment of possible OSA were invited to participate.
6
7

8 9 *Measurements*

10
11 Height, weight, body mass index (BMI), neck circumference, blood pressure and Epworth
12
13 Sleepiness Scale (ESS)(26) were completed at the Sleep Clinic. Participants attended the
14
15 Sleep Laboratory on a separate day so that a Sleep Physiologist could provide, and instruct on
16
17 fitting, a sleep study device. On that occasion, relevant symptoms and co-morbidities were
18
19 recorded, Mallampatti score was assessed, and the Berlin and STOP-BANG Questionnaires
20
21 were completed. Blood samples including non-fasting lipid profile, glycated haemoglobin
22
23 (HbA1c) and C-reactive protein (CRP) were taken. Two fractional exhaled nitric oxide
24
25 ($F_{E}NO$) measurements were taken using the NIOX MINO[®] (Aerocrine, Solna, Sweden), and
26
27 the mean calculated.
28
29
30
31
32

33 34 *Sleep Studies*

35
36 Unattended home limited polygraphy sleep studies were performed using the SOMNOmedics
37
38 SOMNOscreen[™] kit (Randersacker, Germany) with channels that recorded body position,
39
40 thoraco-abdominal movements, oronasal airflow, heart rate, pulse oximetry and snoring.
41
42 Sleep ~~studies~~-study scoring by experienced Sleep Physiologists was in accordance with
43
44 accepted guidelines.(27) An apnoea was defined as cessation of nasal flow for ≥ 10 seconds,
45
46 whilst a hypnoea was defined as 50% reduction in nasal flow for ≥ 10 seconds, or lesser
47
48 reduction in flow associated with oxygen desaturation of $\geq 4\%$.
49
50
51
52
53

54 55 *The Epworth Sleepiness Scale (ESS), Berlin, STOP and STOP-BANG Questionnaires*

56
57
58
59
60

1
2
3 The ESS is a validated measure of daytime sleepiness including eight questions, each with
4 four possible responses, that assesses the likelihood of dozing in different situations; a score
5 of $\geq 11/24$ denotes excessive daytime somnolence.(26) The Berlin Questionnaire includes
6 questions in three categories that relate firstly to snoring and witnessed apnoeas, secondly, to
7 tiredness, fatigue and sleepiness, and thirdly, to hypertension and obesity.(15) High risk of
8 OSA is defined by scoring positively in ≥ 2 categories. The STOP Questionnaire includes
9 four yes/no questions that relate to Snoring, Tiredness, Observed apnoeas and high blood
10 Pressure.(23) High risk of OSA is defined as a score of ≥ 2 . The STOP-BANG Questionnaire
11 includes four additional questions relating to BMI, Age, Neck circumference and Gender, and
12 high risk of OSA is defined as a score of ≥ 3 .(23)
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 *Statistical analyses*

28
29 Statistical analyses were carried out using GraphPad Prism 5, IBM SPSS Statistics 19 and
30 STATA 12. Normality of data was checked using D'Agostino & Pearson omnibus normality
31 test. A priori, two cut-points were chosen for AHI: ≥ 5 events/hour (the standard cut-point
32 for the diagnosis of OSA),(28) and ≥ 15 events/hour, to predict significant SDB (the standard
33 cut-point for initiating continuous positive airway pressure [CPAP] therapy).(28) Groups
34 were compared using unpaired t-tests, Mann-Whitney tests and Fisher's Exact tests as
35 appropriate. Sensitivities, specificities, positive and negative predictive values, positive and
36 negative likelihood ratios, and overall accuracies were calculated for each of the
37 questionnaires for prediction of SDB as defined by AHI cut-points of ≥ 5 and ≥ 15 .
38 Associations between individual variables and each of the cut-points for AHI were explored
39 using univariate and multivariate logistic regression. For multivariate analysis, in a few cases
40 where BMI was known but neck circumference was not known, a value for the neck
41 circumference was imputed using linear regression with BMI as the independent value. This
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 allowed for a dataset of 116 cases with all of the variables known or imputed to be built to
4 identify independent variables for inclusion in a composite score. Receiver operating
5 characteristic (ROC) curve analysis was used to assess predictive value and an area under the
6 curve (AUC) >0.7 was considered clinically significant. Data are presented as mean
7 (standard deviation), median (interquartile range) and proportion (percentage), unless stated
8 otherwise. A p value <0.05 was considered statistically significant.
9
10
11
12
13
14
15
16
17

18 **Results**

19
20 150 subjects participated in this study, of which 129 had adequate sleep study data and were
21 included in the analysis. AHI was ≥ 5 in 97/129 (75%) and ≥ 15 in 56/129 (43%). Overall, 82
22 (64%) were male, mean(SD) age was 49(11) years, and median(IQR) BMI was 32(29-39)
23 kg/m².
24
25
26
27
28
29
30
31

32 *Predicting SDB: Patient characteristics (See Table 1)*

33
34 An AHI <5 (“rule-out measurement”) was associated with female sex, younger age, lower
35 weight and neck circumference, less frequently reported witnessed apnoeas, higher high
36 density lipoprotein (HDL) cholesterol, and lower triglycerides, cholesterol/HDL and HbA1c.
37
38 An AHI ≥ 15 (“rule-in measurement”) was associated with male sex, obesity, higher weight,
39 BMI and neck circumference, more frequently reported hypertension and witnessed apnoeas,
40 lower HDL cholesterol, and higher triglycerides, cholesterol/HDL and HbA1c.
41
42
43
44
45
46
47
48

49 *Predicting SDB: ESS, Berlin, STOP and STOP-BANG (See Tables 2, 3 and 4)*

50
51 The ESS and Berlin questionnaire outcomes were not associated with either AHI cut-point.
52
53 An AHI <5 was associated with lower STOP and STOP-BANG scores, and fewer subjects
54 being classified as “high risk” for OSA by both STOP and STOP-BANG questionnaires. An
55
56
57
58
59
60

1
2
3 AHI \geq 15 was associated with higher STOP and STOP-BANG scores and more subjects being
4 classified as “high risk” for OSA by the STOP-BANG questionnaire but not by the STOP
5
6
7 questionnaire.
8
9

10
11 For the AHI cut-point of \geq 5, the Berlin, STOP, and STOP-BANG questionnaires had high
12 sensitivities, moderate positive predictive values (PPV) and poor specificities and negative
13 predictive values (NPV), for prediction of SDB. The STOP-BANG questionnaire performed
14 best with an overall accuracy of 79%. For the AHI cut-point of \geq 15, the Berlin questionnaire
15 had high sensitivity, but otherwise performed poorly. The STOP and STOP-BANG
16 questionnaires had high sensitivities and NPVs. Again, the STOP-BANG questionnaire
17 performed best, but with a low overall accuracy of 56%. The low negative likelihood ratios
18 for the STOP and STOP-BANG questionnaires at both cut-points indicate that these
19 questionnaires have value in excluding disease. As shown in table 4, the cut-points for
20 STOP-BANG score that were associated with best overall accuracy were \geq 3 and \geq 6 for
21 prediction of AHI \geq 5 and \geq 15, respectively.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 *SDB versus no SDB: Predictors and a composite score (See Tables 5 and 6 and Figure 1)*

39
40 For the cut-point of AHI of \geq 5, univariate logistic regression showed significant associations
41 for age, gender, weight, neck circumference, witnessed apnoeas, triglycerides and
42 cholesterol/HDL ($p<0.05$). For the cut-point of \geq 15, significant associations were found for
43 gender, weight, BMI, neck circumference, witnessed apnoeas, obesity, hypertension, FeNO
44 and cholesterol/HDL ($p<0.05$). Multivariate logistic regression based on the significant
45 variables from univariate logistic regression showed that for both cut-points neck
46 circumference and witnessed apnoeas were independent predictors of SDB. For the cut-point
47 of AHI of \geq 5, in a model incorporating neck circumference and witnessed apnoeas, the
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 probability of SDB was 0.94 for individuals with neck circumference ≥ 17 in and witnessed
4 apnoeas (sensitivity 84%, overall accuracy 77%, ROC AUC 0.768, $p < 0.001$). For the cut-
5 point of AHI ≥ 15 , the probability of SDB was 0.69 for individuals with neck circumference
6 ≥ 17 in and witnessed apnoeas (specificity 80%, overall accuracy 69%, ROC AUC 0.722,
7 $p < 0.001$).

16 Discussion

17
18 This is the first study to prospectively evaluate the utility of the Berlin, STOP and STOP-
19 BANG questionnaires in prediction of sleep disordered breathing in a population referred to a
20 tertiary sleep service for assessment of possible OSA. We found that in this population the
21 Berlin Questionnaire had no significant association with cut-points of ≥ 5 or ≥ 15 for AHI, but
22 that both the STOP and STOP-BANG scores were significantly associated with both cut-
23 points. The STOP-BANG Questionnaire had better performance for the prediction of OSA on
24 home sleep study, and different cut-points for STOP-BANG score could be selected
25 depending on preference to exclude SDB (score < 3) or predict SDB (score ≥ 6). In addition,
26 we found notable associations between sleep study results and several patient characteristics.
27 In particular, neck circumference and witnessed apnoeas were found to be independent
28 predictors of SDB in our population.

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45 In our study, the Berlin Questionnaire was almost ubiquitously positive (116 of 125
46 participants had a positive result) and the positivity rate did not differ between those with and
47 without SDB. This was expected as this questionnaire was designed for primary care
48 assessment and our study population consisted of individuals referred from primary care with
49 symptoms suggestive of SDB. Our results indicate that the Berlin Questionnaire is not useful
50 in the prediction of SDB in the sleep clinic referral population and this is consistent with
51
52
53
54
55
56
57
58
59
60

1
2
3 previous reports.(19) ~~However, t~~The high sensitivities obtained for both AHI cut-points
4 support previous findings that the Berlin Questionnaire may have a role as a “rule-out”
5 measurement in the primary care or screening setting(15, 17, 20, 24), though there have been
6 some conflicting results, suggesting it does not have adequate discriminatory power.(16, 22)
7
8
9

10
11
12
13
14 In our study Epworth Sleepiness Scale data indicated that two thirds of participants had
15 excessive daytime somnolence (ESS ≥ 11), however scores were similar in individuals with or
16 without SDB. Therefore, at least in the sleep clinic population, the ESS ~~does not have utility~~
17 ~~in is not useful for~~ the prediction of SDB. ~~Nevertheless, it~~ may ~~be of value, be clinically~~
18 ~~useful in other respects~~ perhaps ~~modified and/or~~ combined with other ~~structured~~
19 ~~questionsmeasures~~, including those highlighted in this study, ~~in prediction of compliance~~
20 with and benefit from OSA treatment ~~in patients with any degree of SDB~~. ~~Further research is~~
21 ~~required to address this question.~~ Exhaled nitric oxide levels were not significantly different
22 between individuals with or without SDB whether defined by an AHI cut-point of ≥ 5 or ≥ 15 .
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

43 We found that both the STOP and STOP-BANG questionnaires have utility in the prediction
44 of SDB in the sleep clinic population, and that STOP-BANG was superior, with higher
45 overall predictive accuracy. The STOP and STOP-BANG Questionnaires were developed
46 and validated in a surgical population using in-laboratory polysomnography(23) and have
47 subsequently been studied in a cardiovascular disease population.(25) Our results are in
48 agreement with these two earlier studies as regards the increased predictive value of STOP-
49 BANG over STOP. In contrast to these earlier studies, however, we found sensitivities to be

1
2
3 higher and specificities to be lower for both cut-points of AHI. ~~This is as expected given that~~
4 ~~we were studying a symptomatic cohort referred to a sleep clinic, rather than a screening~~
5 ~~population, and this is also a desirable outcome for these questionnaires in situations where~~
6 ~~missing even mild OSA would be undesirable.~~ We suggest that of the two AHI cut-points,
7 >15 events/hr is the more important, being diagnostic of at least moderate SDB and also an
8 indication for CPAP treatment. At this cut-point, STOP and STOP-BANG performed with
9 high sensitivities and negative predictive values (STOP-BANG superior to STOP) indicating
10 that these questionnaires are more useful in excluding significant SDB. This is further
11 corroborated by the negative likelihood ratios of <0.2 obtained for STOP and STOP-BANG
12 that also indicate that these questionnaires are ~~likely~~ most useful ~~for in predicting low risk of~~
13 ~~confirming ruling out~~ SDB. The STOP-BANG ~~:-these~~ may be of ~~future~~ value in ~~combination~~
14 ~~in~~ the primary care setting, perhaps combined with type IV portable monitoring~~screening~~
15 sleep studies, to determine requirement for sleep clinic review and more detailed polygraphy.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34 At the AHI cut-point of ≥ 15 , STOP-BANG had sensitivity and negative predictive value of
35 100%, and since this is the standard cut-point conventionally used to determine need for
36 CPAP,(28) we suggest that the STOP-BANG questionnaire is the preferred tool for prediction
37 of SDB in the sleep clinic setting of those currently available. STOP-BANG, perhaps with
38 modifications, ~~merits seems worthwhile for~~ further exploration evaluation for the prediction of
39 sleep study findings~~SDB~~ in a larger the sleep clinic cohort population and, more importantly,
40 its utility in prediction of clinical outcomes including treatment success ~~in symptomatic and~~
41 ~~screening populations~~should be assessed.

42
43
44
45
46
47
48
49
50
51
52
53
54 The original STOP-BANG questionnaire uses a cut-point of ≥ 3 to predict SDB.(23)
55
56 However, in our study we show that different cut-points can be selected depending on the
57
58
59
60

1
2
3 preference to rule-in or rule-out SDB. A score of ≥ 3 had the highest overall accuracy and a
4
5 sensitivity of 0.93 for the AHI cut-point of ≥ 5 , whereas a score of ≥ 6 had the highest overall
6
7 accuracy and a specificity of 0.78 for the AHI cut-point of ≥ 15 . Two other studies have
8
9 examined the usefulness of different cut-points for STOP-BANG score.(33-34) In the obese,
10
11 a score of ≥ 3 was associated with a sensitivity of 0.90 for predicting an AHI >5 , whilst, a
12
13 score of ≥ 6 had a specificity of 0.88 for predicting an AHI >15 and similar results ~~were have~~
14
15 been obtained in the morbidly obese(33) and in ~~another~~ surgical population.(34) Thus, in the
16
17 sleep clinic setting where the ultimate goal is to identify patients requiring CPAP, a higher
18
19 cut-point for STOP-BANG may be preferred whereas in a primary care setting where the
20
21 priority is not to miss disease a lower cut-point may be chosen.
22
23
24
25

26
27 The STOP-BANG questionnaire is, however, still an imperfect tool for prediction of results
28
29 on home polygraphy. Accordingly, the secondary objective of our study was to identify ~~those~~
30
31 variables for inclusion, ~~and how they should be weighted~~ in a locally developed composite
32
33 score for future validation in the sleep clinic and potentially wider population. Univariate
34
35 analysis showed several significant, expected associations for both cut-points of AHI. Using
36
37 multivariate analysis, neck circumference ≥ 17 in and the presence of witnessed apnoeas were
38
39 independent predictors of SDB. This is not a novel finding, but does support the robustness
40
41 of our data. Particularly when SDB was defined by an AHI cut-point of ≥ 5 , the regression
42
43 model derived indicated a high probability of SDB of 0.94 if both factors were present. The
44
45 STOP-BANG questionnaire, of course, includes both of these variables, and it is possible that
46
47 adjustment of the inclusion variables, or their weighting, might improve its performance. In
48
49 future work, we aim to validate a simple composite score based on these two variables in a
50
51 modification of ~~the STOP-BANG Questionnaire~~, to determine utility for predicting sleep
52
53 study data and outcomes with treatment.
54
55
56
57
58
59
60

1
2
3
4
5 Ultimately, a predictive tool that can be utilised in primary care is the goal. Our results
6 indicate low specificity of STOP-BANG, and therefore in its current form, if used in primary
7 care to identify patients requiring referral for further assessment, it is likely to result in a
8 significant percentage of patients being referred unnecessarily (false positives). It is hoped
9 that a modified STOP-BANG with improved specificity, while not compromising sensitivity,
10 may be developed that can be used safely in primary care for identification of patients
11 requiring referral to sleep services. Of utmost importance too is the prediction of treatment
12 outcome. Non-adherence to CPAP treatment occurs in between 46 and 83%.(35-36)
13 Prediction of poor adherence by STOP-BANG or other similar tools would allow greater
14 attention to interventions to improve adherence in patients more likely to default from
15 treatment. The authors are not aware of any studies investigating this question and future
16 research should explore this important issue.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 A possible limitation of our study was that SDB was characterised using home unattended
35 limited sleep studies rather than in-hospital attended full polysomnography. The latter is
36 considered the gold standard for diagnosis of SDB but is more expensive, less easily accessed
37 and potentially unrepresentative with sleep in an unfamiliar environment. Home unattended
38 and in-hospital attended sleep studies have previously been shown to produce similar results.
39
40 (37) Accordingly home testing with portable monitors is standard clinical practice in the UK,
41 and is now considered an acceptable method for diagnosis of OSA by the American Academy
42 of Sleep Medicine.(28) The sample size limits the conclusions that can be drawn from
43 multivariate analysis, however this was a secondary objective of the current study. It is
44 possible that variables predictive of SDB on univariate analysis in this cohort would have
45 been identified as independently predictive in multivariate models in a larger population. The
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 results of this study allow us, and potentially others, to focus future work to validate more
4
5 extensively the results obtained to date. We chose AHI cut-points of ≥ 5 and ≥ 15 to define
6
7 significant SDB. This was based on the consensus guideline produced by the Adult
8
9 Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine that states
10
11 that diagnosis of OSA is based on a cut-point of >15 events/hr or >5 events/hr with relevant
12
13 symptoms, and that CPAP is indicated for treatment of moderate to severe OSA with ≥ 15
14
15 events/hr.(28) Although the cut-point of >30 events/hr is consistent with severe OSA we
16
17 suggest that this cut-point is less clinically relevant from a diagnostic perspective or from that
18
19 of determining treatment. Finally, due to the prospective design of our study, we cannot
20
21 comment on the relative value of other tools developed for prediction of OSA such as the
22
23 Sleep Apnea Clinical Score (38) and American Society of Anesthesiologists Checklist. (39)
24
25 To compare their utility with that of the Berlin, STOP and STOP-BANG questionnaires in the
26
27 population referred to the sleep service would require a further study.
28
29
30
31
32
33

34 In conclusion, the Berlin Questionnaire was not useful in the prediction of SDB within our
35
36 sleep clinic population. The STOP-BANG questionnaire had superior predictive performance
37
38 to the STOP questionnaire at both cut-points of AHI (≥ 5 and ≥ 15). A STOP-BANG score of
39
40 ≥ 3 had the highest overall accuracy and a sensitivity of 0.93 for the prediction of an AHI ≥ 5 ,
41
42 whilst a score of ≥ 6 had the highest overall accuracy and a specificity of 0.78 for the
43
44 prediction of an AHI ≥ 15 . Future work will validate a composite score including neck
45
46 circumference ≥ 17 in and the presence of witnessed apnoeas for the prediction of SDB in the
47
48 sleep clinic referral population. An optimised composite score could then be, with possibility
49
50 then of evaluating evaluated in primary care and against treatment outcomes, with our overall
51
52 aim being to provide required tools for use in the expanded and consolidated sleep services
53
54 that are now necessary; given the current obesity and OSA epidemics.
55
56
57
58
59
60

References

1. Young T, Palta M, Dempsey J, et al. The occurrence of sleep-disordered breathing among middle-aged adults. *N Engl J Med*. 1993 ;**328**:1230-5.
2. Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. *Lancet*. 2013; published online DOI:10.1016/S0140-6736(13)60734-5.
3. McNicholas WT. Diagnosis of obstructive sleep apnea in adults. *Proc Am Thorac Soc*. 2008;**5**:154-60.
4. Lacasse Y, Godbout C, Series F. Health-related quality of life in obstructive sleep apnoea. *Eur Respir J*. 2002;**19**:499-503.
5. Engleman HM, Douglas NJ. Sleep. 4: Sleepiness, cognitive function, and quality of life in obstructive sleep apnoea/hypopnoea syndrome. *Thorax*. 2004;**59**:618-22.
6. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. *N Engl J Med*. 1999;**340**:847-51.
7. Robinson GV, Stradling JR, Davies RJ. Sleep . 6: obstructive sleep apnoea/hypopnoea syndrome and hypertension. *Thorax*. 2004;**59**:1089-94.
8. Lattimore JD, Celermajer DS, Wilcox I. Obstructive sleep apnea and cardiovascular disease. *J Am Coll Cardiol*. 2003;**41**:1429-37.
9. Svatikova A, Wolk R, Gami AS, et al. Interactions between obstructive sleep apnea and the metabolic syndrome. *Curr Diab Rep*. 2005;**5**:53-8.
10. Meslier N, Gagnadoux F, Giraud P, et al. Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. *Eur Respir J*. 2003;**22**:156-60.
11. Young T, Evans L, Finn L, et al. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. *Sleep*. 1997;**20**:705-6.
12. Heffner JE, Rozenfeld Y, Kai M, et al. Prevalence of diagnosed sleep apnea among patients with type 2 diabetes in primary care. *Chest*. 2012;**141**:1414-21.
13. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. *Int J Pediatr Obes*. 2006;**1**:11-25.
14. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. *JAMA*. 2002;**288**:1723-7.
15. Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. *Ann Intern Med*. 1999;**131**:485-91.
16. Sert Kuniyoshi FH, Zellmer MR, Calvin AD, et al. Diagnostic accuracy of the Berlin Questionnaire in detecting sleep-disordered breathing in patients with a recent myocardial infarction. *Chest*. 2011;**140**:1192-7.
17. Best MW, Fitzpatrick M, Milev R, et al. Utility of the Berlin questionnaire for predicting obstructive sleep apnea in individuals with treatment-resistant depression. *Sleep Breath*. 2013; published online DOI:10.1007/s11325-013-0827-2.
18. Kang K, Park KS, Kim JE, et al. Usefulness of the Berlin Questionnaire to identify patients at high risk for obstructive sleep apnea: a population-based door-to-door study. *Sleep Breath*. 2013;**17**:803-10.
19. Ahmadi N, Chung SA, Gibbs A, et al. The Berlin questionnaire for sleep apnea in a sleep clinic population: relationship to polysomnographic measurement of respiratory disturbance. *Sleep Breath*. 2008;**12**:39-45.
20. Bouloukaki I, Komninos ID, Mermigkis C, et al. Translation and validation of Berlin questionnaire in primary health care in Greece. *BMC Pulm Med*. 2013;**13**:6.

21. Saleh AB, Ahmad MA, Awadalla NJ. Development of Arabic version of Berlin questionnaire to identify obstructive sleep apnea at risk patients. *Ann Thorac Med.* 2011 ;**6**:212-6.
22. Sforza E, Chouchou F, Pichot V, et al. Is the Berlin questionnaire a useful tool to diagnose obstructive sleep apnea in the elderly? *Sleep Med.* 2011;**12**:142-6.
23. Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. *Anesthesiology.* 2008 ;**108**:812-21.
24. Chung F, Yegneswaran B, Liao P, et al. Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. *Anesthesiology.* 2008 ;**108**:822-30.
25. Silva GE, Vana KD, Goodwin JL, et al. Identification of patients with sleep disordered breathing: comparing the four-variable screening tool, STOP, STOP-Bang, and Epworth Sleepiness Scales. *J Clin Sleep Med.* 2011;**7**:467-72.
26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep.* 1991;**14**:540-5.
27. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. *Sleep.* 1999;**22**:667-89.
28. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med.* 2009;**5**:263-76.
29. Chua AP, Aboussouan LS, Minai OA, et al. Long-term continuous positive airway pressure therapy normalizes high exhaled nitric oxide levels in obstructive sleep apnea. *J Clin Sleep Med.* 2013;**9**:529-35.
30. Fortuna AM, Miralda R, Calaf N, et al. Airway and alveolar nitric oxide measurements in obstructive sleep apnea syndrome. *Respir Med.* 2011 ;**105**:630-6.
31. Depalo A, Carpagnano GE, Spanevello A, et al. Exhaled NO and iNOS expression in sputum cells of healthy, obese and OSA subjects. *J Intern Med.* 2008;**263**:70-8.
32. Agustí AG, Barbe F, Togo B. Exhaled nitric oxide in patients with sleep apnea. *Sleep.* 1999;**22**:231-5.
33. Chung F, Yang Y, Liao P. Predictive Performance of the STOP-Bang Score for Identifying Obstructive Sleep Apnea in Obese Patients. *Obes Surg.* 2013; published online DOI:10.1007/s11695-013-1006-z.
34. Chung F, Subramanyam R, Liao P, et al. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. *Br J Anaesth.* 2012 ;**108**:768-75.
35. Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. *Proc Am Thorac Soc.* 2008;**5**:173-8.
36. Wolkove N, Baltzan M, Kamel H, et al. Long-term compliance with continuous positive airway pressure in patients with obstructive sleep apnea. *Can Respir J.* 2008;**15**:365-9.
37. Iber C, Redline S, Kaplan Gilpin AM, et al. Polysomnography performed in the unattended home versus the attended laboratory setting--Sleep Heart Health Study methodology. *Sleep.* 2004;**27**:536-40.
38. Flemons WW, Whitelaw WA, Brant R, et al. Likelihood ratios for a sleep apnea clinical prediction rule. *Am J Respir Crit Care Med.* 1994;**150**:1279-85.
39. Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. *Anesthesiology.* 2006 ;**104**:1081-93.

Table 1: Comparison of patient characteristics including anthropometric measurements, co-morbidities, symptoms, inflammatory markers, lipid profile and oximetry between groups without and with SDB as defined by AHI <5 events/hour and ≥ 15 events/hour.

	<i>AHI<5</i>	<i>AHI\geq5</i>	<i>p</i>	<i>AHI<15</i>	<i>AHI\geq15</i>	<i>P</i>
<i>Male gender</i>	15/32 (47%)	67/97 (69%)	0.034	38/73 (52%)	44/56 (79%)	0.003
<i>Age (yrs)</i>	44 (12)	51 (11)	0.004	48 (13)	51 (9)	0.103
<i>Weight (kg)</i>	89 (19)	101 (22)	0.022	92 (21)	107 (20)	0.001
<i>BMI (kg/m²)</i>	31 (28-36)	33 (29-40)	0.118	31 (27-36)	34 (31-41)	0.009
<i>Obesity (BMI\geq30 kg/m²)</i>	18/28 (64%)	61/85 (72%)	0.482	38/63 (60%)	41/50 (82%)	0.014
<i>Neck circumference (in)</i>	15 (2)	17(2)	<0.001	16 (2)	17 (1)	<0.001
<i>Neck circumference \geq17in</i>	4/22 (18%)	45/76 (59%)	0.001	18/54 (33%)	31/44 (70%)	<0.001
<i>Mallampatti</i>	2 (1)	2 (1)	0.192	2 (1)	2 (1)	0.900
<i>SBP (mmHg)</i>	134 (17)	136 (16)	0.480	134 (15)	138 (18)	0.194
<i>DBP (mmHg)</i>	82 (11)	83 (9)	0.528	81 (10)	85 (10)	0.086
<i>Diabetes</i>	2/32 (6%)	6/97 (6%)	1.000	4/73 (5%)	4/56 (7%)	0.727
<i>Hypertension</i>	7/32 (22%)	36/97 (37%)	0.134	18/73 (25%)	25/56 (45%)	0.024
<i>Hyperlipidaemia</i>	2/32 (6%)	18/97 (19%)	0.156	10/73 (14%)	10/56 (18%)	0.625
<i>Loud snorer</i>	28/32 (88%)	92/97 (95%)	0.224	65/73 (89%)	55/56 (98%)	0.077
<i>Witnessed apnoeas</i>	15/32 (47%)	72/97 (74%)	0.008	40/73 (55%)	47/56 (84%)	<0.001
<i>Nocturia*</i>	11/32 (34%)	38/97 (39%)	0.679	26/73 (36%)	23/56 (41%)	0.585
<i>Nocturnal wakenings*</i>	18/32 (56%)	65/97 (67%)	0.293	46/73 (63%)	37/56 (66%)	0.853
<i>Nocturnal choking</i>	15/32 (47%)	35/97 (36%)	0.301	28/73 (38%)	22/56 (39%)	1.000
<i>Nocturnal gasping</i>	11/32 (34%)	38/97 (39%)	0.679	26/73 (36%)	23/56 (41%)	0.585
<i>F_eNO (ppb)</i>	15 (12-25)	18 (12-26)	0.595	15 (11-24)	19 (12-27)	0.050
<i>Cholesterol (mmol/L)</i>	5.2 (1.1)	5.4 (1.0)	0.431	5.3 (1.1)	5.4 (0.9)	0.674
<i>HDL cholesterol (mmol/L)</i>	1.3 (1.0-1.5)	1.1 (1.0-1.3)	0.008	1.2 (1.0-1.4)	1.1 (1.0-1.2)	0.016
<i>Triglycerides (mmol/L)</i>	1.9 (1.0-2.5)	2.2 (1.5-3.2)	0.015	1.9 (1.3-2.9)	2.3 (1.6-3.2)	0.042
<i>Cholesterol/HDL</i>	4.1 (3.3-5.0)	4.7 (3.8-5.7)	0.011	4.3 (3.5-5.6)	4.8 (4.0-5.8)	0.022
<i>HbA1c (mmol/mol)</i>	34 (32-37)	38 (36-41)	0.001	36 (33-39)	38 (36-42)	0.002
<i>CRP</i>	3.0 (1.2-8.5)	3.8 (1.4-7.5)	0.608	3.0 (1.3-7.6)	4.3 (1.4-8.6)	0.173

Legend for Table 1: Data presented as mean (standard deviation), median (interquartile

range) or proportion (percentage) as appropriate. Significant differences in bold. * ≥ 2 /night.

Abbreviations: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; F_eNO, fraction of exhaled nitric oxide; HDL, high density lipoprotein; HbA1c, glycated haemoglobin; CRP, C-reactive protein; ODI, oxygen desaturation index; SpO₂, oxygen saturation; SpO₂ t<90, duration of time for which oxygen saturation less than 90%.

Table 2: Comparison of results of Epworth Sleepiness Scale (ESS) and Berlin, STOP and STOP-BANG Questionnaires between groups without and with SDB as defined by AHI <5 events/hour and ≥ 15 events/hour.

	<i>AHI</i> <5	<i>AHI</i> \geq 5	<i>p</i>	<i>AHI</i> <15	<i>AHI</i> \geq 15	<i>p</i>
<i>ESS score</i>	13 (8-16)	13 (7-17)	0.845	13 (7-16)	13 (9-18)	0.476
<i>ESS +ve ($\geq 11/24$)</i>	17/28 (61%)	63/92 (68%)	0.496	42/66 (64%)	38/54 (70%)	0.560
<i>Berlin +ve</i>	29/31 (94%)	87/94 (93%)	1.000	65/71 (92%)	51/54 (94%)	0.731
<i>STOP score</i>	2.5 (2-3)	3 (2-3)	0.011	3 (2-3)	3 (3-3.5)	<0.001
<i>STOP +ve ($\geq 2/4$)</i>	27/32 (84%)	93/96 (97%)	0.023	66/73 (90%)	54/55 (98%)	0.137
<i>STOP-BANG score</i>	4 (2-5)	5 (5-6)	<0.001	5 (2-5)	6 (5-6)	<0.001
<i>STOP-BANG +ve ($\geq 3/8$)</i>	21/30 (70%)	88/93 (95%)	<0.001	54/68 (79%)	55/55 (100%)	<0.001

Legend for Table 2: Data presented as median (interquartile range) or proportion (percentage)

as appropriate. Significant differences in bold.

Table 3: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), likelihood ratios positive (LR+), likelihood ratios negative (LR-), and overall accuracies of the Berlin, STOP and STOP-BANG Questionnaires for prediction of significant SDB as defined by: A: AHI \geq 5 events/hour; B: AHI \geq 15 events/hour.

A: Cut-point = AHI \geq 5 events/hour

	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
<i>Berlin</i>	0.93 (0.85-0.97)	0.06 (0.01-0.21)	0.75 (0.66-0.83)	0.22 (0.03-0.60)	0.99	1.15	71%
<i>STOP</i>	0.97 (0.91-0.99)	0.16 (0.05-0.33)	0.78 (0.69-0.85)	0.62 (0.24-0.91)	1.15	0.20	77%
<i>STOP-BANG</i>	0.95 (0.88-0.98)	0.30 (0.15-0.49)	0.81 (0.72-0.88)	0.64 (0.35-0.87)	1.35	0.18	79%

B: Cut-point = AHI \geq 15 events/hour

	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
<i>Berlin</i>	0.94 (0.85-0.99)	0.08 (0.03-0.17)	0.44 (0.35-0.53)	0.67 (0.30-0.92)	1.03	0.66	46%
<i>STOP</i>	0.98 (0.90-1.00)	0.10 (0.04-0.19)	0.45 (0.36-0.54)	0.88 (0.47-1.00)	1.09	0.19	48%
<i>STOP-BANG</i>	1.00 (0.94-1.00)	0.21 (0.12-0.32)	0.50 (0.41-0.60)	1.00 (0.77-1.00)	1.26	0.00	56%

Legend for Table 3: Data presented with 95% confidence intervals.

Table 4: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), likelihood ratios positive (LR+), likelihood ratios negative (LR-), and overall accuracies of different cut-points of the STOP-BANG questionnaire for prediction of significant SDB as defined by: A: AHI ≥ 5 events/hour; B: AHI ≥ 15 events/hour.

A: Cut-point = AHI ≥ 5 events/hour

<i>STOP-BANG cut-point (/8)</i>	<i>Proportion +ve SB</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
≥ 2	92/96	0.99 (0.92-1.00)	0.12 (0.03-0.32)	0.77 (0.67-0.85)	0.75 (0.19-0.99)	1.13	0.11	77%
≥ 3	82/96	0.93 (0.84-0.98)	0.38 (0.19-0.59)	0.82 (0.72-0.89)	0.64 (0.35-0.87)	1.49	0.18	79%
≥ 4	79/96	0.90 (0.81-0.96)	0.42 (0.22-0.63)	0.82 (0.72-0.90)	0.59 (0.33-0.82)	1.55	0.23	78%
≥ 5	67/96	0.81 (0.70-0.89)	0.62 (0.41-0.81)	0.87 (0.76-0.94)	0.52 (0.32-0.71)	2.15	0.31	76%
≥ 6	38/96	0.46 (0.34-0.58)	0.79 (0.58-0.93)	0.87 (0.72-0.96)	0.33 (0.21-0.46)	2.20	0.68	54%
≥ 7	15/96	0.18 (0.10-0.29)	0.92 (0.73-0.99)	0.87 (0.60-0.98)	0.27 (0.18-0.38)	2.17	0.89	36%
8	5/96	0.07 (0.02-0.15)	1.00 (0.86-1.00)	1.00 (0.48-1.00)	0.26 (0.18-0.37)	-	0.93	30%

B: Cut-point = AHI ≥ 15 events/hour

<i>STOP-BANG cut-point (/8)</i>	<i>Proportion +ve SB</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>LR+</i>	<i>LR-</i>	<i>Accuracy</i>
≥ 2	92/96	1.00 (0.91-1.00)	0.07 (0.02-0.18)	0.45 (0.34-0.55)	1.00 (0.40-1.00)	1.08	0	47%
≥ 3	82/96	1.00 (0.91-1.00)	0.25 (0.15-0.39)	0.50 (0.39-0.61)	1.00 (0.77-1.00)	1.34	0	57%
≥ 4	79/96	1.00 (0.91-1.00)	0.31 (0.19-0.45)	0.52 (0.40-0.63)	1.00 (0.80-1.00)	1.45	0	60%
≥ 5	67/96	0.93 (0.80-0.98)	0.47 (0.34-0.61)	0.57 (0.44-0.69)	0.90 (0.73-0.98)	1.76	0.15	67%
≥ 6	38/96	0.63 (0.47-0.78)	0.78 (0.65-0.88)	0.68 (0.51-0.82)	0.74 (0.61-0.85)	2.91	0.47	72%
≥ 7	15/96	0.22 (0.11-0.38)	0.89 (0.78-0.96)	0.60 (0.32-0.84)	0.60 (0.49-0.71)	2.01	0.88	60%
8	5/96	0.10 (0.03-0.23)	0.98 (0.90-1.00)	0.80 (0.28-0.99)	0.59 (0.48-0.70)	5.36	0.92	60%

Legend for Table 4: Data presented with 95% confidence intervals. Abbreviations: SB,

STOP-BANG.

Table 5: Probabilities of SDB using a composite score based on neck circumference (≥ 17 in or < 17 in) and presence (1) or absence (0) of witnessed apnoeas derived from logistic regression models. SDB defined by: A: AHI ≥ 5 events/hour; B: AHI ≥ 15 events/hour.

A: Cut-point = AHI ≥ 5 events/hour

<i>Neck Circumference (in)</i>	<i>Witnessed Apnoeas</i>	
	<i>0</i>	<i>1</i>
<i><17</i>	0.47	0.75
<i>≥ 17</i>	0.83	0.94

B: Cut-point = AHI ≥ 15 events/hour

<i>Neck Circumference (in)</i>	<i>Witnessed Apnoeas</i>	
	<i>0</i>	<i>1</i>
<i><17</i>	0.17	0.40
<i>≥ 17</i>	0.40	0.69

Table 6: Sensitivities, specificities, positive predictive values (PPV), negative predictive values (NPV), and overall accuracies of logistic models for prediction of SDB as defined by:

A: AHI ≥ 5 events/hour; predict SDB *unless* neck < 17 in *and* witnessed apnoeas absent; B:

AHI ≥ 15 events/hour; predict SDB *only if* neck ≥ 17 in *and* witnessed apnoeas present.

<i>Model</i>	<i>Sensitivity</i>	<i>Specificity</i>	<i>PPV</i>	<i>NPV</i>	<i>Accuracy</i>
A	0.84 (0.75-0.91)	0.54 (0.34-0.72)	0.85 (0.76-0.92)	0.52 (0.32-0.71)	77%
B	0.56 (0.41-0.70)	0.80 (0.68-0.89)	0.69 (0.53-0.82)	0.69 (0.57-0.79)	69%

Legend for Table 6: Data presented with 95% confidence intervals.

Figure 1: ROC curves of logistic models for prediction of SDB as defined by: **Model A:** AHI ≥ 5 events/hour; predict SDB *unless* neck < 17 in and witnessed apnoeas absent; **Model B:** AHI ≥ 15 events/hour; predict SDB *only if* neck ≥ 17 in and witnessed apnoeas present.

Model A:

Model B:

Contributorship Statement:

Douglas Cowan took a leading role in study protocol development, study document development, application for ethics approval, data collection, statistical analysis and paper writing.

Gwen Allardice provided statistical support and performed part of the statistical analysis.

Duncan MacFarlane, Darren Ramsay and Heather Ambler contributed to data collection, and carried out and scored sleep studies.

Stephen Banham contributed to study protocol development.


Eric Livingston contributed to study protocol development, study document development, application for ethics approval and paper writing.

Christopher Carlin contributed to study protocol development, data collection, statistical analysis and paper writing.

All authors approved the final draft before submission.

Christopher Carlin is responsible for the overall content as guarantor.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



139x101mm (300 x 300 DPI)

View only

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation	Page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	NA
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	NA
		(e) Describe any sensitivity analyses	

Results		Page	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9,18
		(b) Indicate number of participants with missing data for each variable of interest	19
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	NA
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	NA
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	9,10,19-23
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	20-21
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10,22-23
Discussion			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	NA

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.